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Summary III 
SUMMARY 
Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the central 
nervous system (CNS) in which remyelination of lesions is often limited or absent. 
Evidence for the involvement of fibroblast growth factor 1 (FGF1) in MS lesion 
development arose from previous work in our laboratory, analyzing the gene 
expression in different types of MS lesions. FGF1 peaked out as an abundant factor 
upregulated in remyelinated areas. The present study aimed at: (1) the establishment 
of an in vitro myelinating culture which could be used to identify FGF1-mediated effects 
on myelination, (2) the detection of FGF1-mediated functions in cultured human 
astrocytes and (3) the identification of FGF1-positive cells in MS lesions. 
An in vitro myelinating culture mimicking developmental myelination was introduced 
in our laboratory. The validity of a microscopy-based method for the quantification of 
myelination and axonal density was proven by antibody-mediated complement 
dependent demyelination. FGF1 was found to promote myelination in this culture 
system (independent study). This effect might be directly mediated by oligodendrocytes 
or indirectly by astrocytes, both known to express FGF receptors (FGFRs).  
To decipher FGF1-mediated effects on primary human astrocytes in cell culture, 
modulations in RNA and protein levels were analyzed by a transcriptome microarray 
analysis and a secretome analysis, respectively. The transcriptome approach revealed 
a FGF1-dependent induction of RNAs involved in modulation of remyelination and the 
regulation of inflammation. Results obtained from the secretome approach pointed to a 
FGF1-mediated disintegration of extracellular matrix (ECM). Results of the screenings 
were validated by reverse transcription quantitative PCR (RT-qPCR) and enzyme-
linked immunosorbent assay (ELISA). Comparison of the results obtained from the 
transcriptome and the secretome approach revealed a correlation of RNA and protein 
levels for the majority of proteins detected in both approaches. 
Using immunohistochemistry (IHC), FGF1-positive subsets of neurons in gray 
matter and oligodendrocytes in white matter of control brain and in normal appearing 
white matter (NAWM) of MS lesions were detected. FGF1-positive astrocytes were 
identified in remyelinated and demyelinated lesions. In active MS lesions, microglia, 
macrophages and lymphocytes were found to be FGF1-positive.  
In the present study, FGF1 was localized to different cells in MS lesions and an 
extensive characterization of FGF1-mediated effects revealed, to our knowledge, so far 
unknown functions in human astrocytes. This strongly suggests FGF1 to be an 
important mediator in MS lesion development. A detailed understanding of FGF1 
functions could provide a therapeutic basis for promoting repair mechanisms in MS. 
IV Zusammenfassung 
ZUSAMMENFASSUNG 
Multiple Sklerose (MS) ist eine demyelinisierende Erkrankung des zentralen 
Nervensystems, in der die Remyelinisierung oft stark limitiert ist. Hinweise auf eine 
Beteiligung des Fibroblasten-Wachstumsfaktors 1 (FGF1) in Multipler Sklerose gingen 
aus einer Studie unseres Labors hervor, in der die Genexpression verschiedener MS 
Läsionen untersucht wurde und in der FGF1 in remyelinisierten Läsionen erhöht war. 
Die Ziele der hier beschriebenen Studie waren: (1) Die Etablierung einer 
Myelinisierungskultur zur Untersuchung von FGF1-vermittelten Effekten auf die 
Myelinisierung. (2) Die Detektion von FGF1-vermittelten Effekten auf humane 
Astrozyten in Zellkultur. (3) Die Identifikation von FGF1-positiven Zellen in MS 
Läsionen. 
Es wurde eine Myelinisierungskultur etabliert, mit der entwicklungsabhängige 
Myelinisierung nachvollzogen werden kann. Zudem wurde eine, auf 
Fluoreszenzmikroskopie basierende Quantifizierungsmethode entwickelt, um die 
Myelinisierung und die Dichte der Axone zu bestimmen. Diese wurde durch Antikörper-
vermittelte, komplementabhängige Zytolyse validiert. In diesem Zellkultursystem wurde 
ein myelinisierungsfördernder Effekt von FGF1 nachgewiesen (unabhängige Studie). 
Dieser könnte direkt von Oligodendrozyten aber auch indirekt von Astrozyten vermittelt 
werden, welche beide FGF Rezeptoren exprimieren. 
Die Effekte von FGF1 auf humane Astrozyten in Zellkultur wurden mithilfe einer 
Transkriptom- und einer Sekretomanalyse untersucht. In der Transkriptomanalyse 
wurden sowohl Faktoren mit Einfluss auf die Remyelinisierung, als auch solche mit 
entzündungsmodulatorischer Wirkung identifiziert. Aus der Sekretomanalyse gingen 
Effekte von FGF1 auf den Abbau von extrazellulärer Matrix hervor. Die Ergebnisse 
beider Analysen wurden mittels RT-qPCR und ELISA validiert. Der Vergleich von 
Proteinen, detektiert in der Sekretomanalyse, mit den Transkriptomergebnissen zeigte 
eine Korrelation zwischen detektierter RNA- und den zugehörigen Proteinen.  
Mittels Immunhistologie wurden zudem FGF1-positive Zellen in verschiedenen 
Läsionsarealen identifiziert. Es wurden FGF1-positive Neurone, sowie FGF1-positive 
Oligodendrozyten in der weißen Substanz von Kontrollhirn und in normal 
erscheinender weißer Substanz (NAWM) von MS Gewebe detektiert. In re- und 
demyelinisierten Regionen wurden Astrozyten detektiert, in aktiven Läsionen hingegen 
Mikroglia, Makrophagen und Lymphozyten. 
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In der vorliegenden Arbeit wurden FGF1-positive Zellen in MS Läsionen detektiert 
und es wurden, nach unserem Wissen, bislang unbekannte FGF1-vermittelte Effekte in 
Astrozyten charakterisiert. Dies stützt die Vermutung, dass FGF1 ein wichtiger 
Modulator in der Pathogenese von MS ist. Ein genaueres Verständnis der von FGF1 
vermittelten Funktionen könnte eine therapeutische Grundlage dafür schaffen, 




1.1 MULTIPLE SCLEROSIS 
Multiple Sclerosis (MS) is considered an autoimmune inflammatory demyelinating 
disease of the central nervous system (CNS). MS is typically affecting people between 
their second and third decade of life and it is one of the most common causes of 
disability in young adults. Around 122 000 patients in Germany and 2.5 million 
worldwide69 suffer from this disease with women being more often affected than men. 
Traditionally, MS was considered to be mediated by T cells attacking CNS structures, 
especially myelin. However, also a vast range of other immune cells do participate in 
the inflammatory process, with T cells, macrophages and microglia being the 
dominating cell types. This leads to demyelinated areas in the white and gray matter of 
the brain, which is the pathological hallmark of MS, to axonal damage and finally to 
neuronal death. Besides demyelination, also inflammation itself is critical for neuronal 
and axonal loss228. Commonly affected sites are the subpial cerebral cortex, the 
periventricular white matter, the optic nerve, the brainstem and the spinal cord.  
The appearance of MS is heterogeneous with a vast spectrum of differences in 
clinical symptoms, lesion number and location as well as in efficacy of available 
therapies111. The symptoms can include impaired physiological and cognitive functions, 
fatigue, disturbance of vision as well as loss of coordination and sometimes paralysis. 
Oligoclonal bands, resulting from immunoglobulin G in the cerebrospinal fluid (CSF), as 
well as transient gadolinium enhanced lesions in magnetic resonance scans, indicating 
an inflammation and the breakdown of the blood-brain barrier (BBB), are often found in 
patients and are used as diagnostic criteria. 
1.1.1 Clinical disease course 
Depending on the clinical course, MS is classified as relapsing remitting (RR), 
primary progressive (PP) or secondary progressive (SP) (figure 1). In the vast majority 
of patients (approximately 85 %), the disease starts with a RR course which is 
characterized by alternating periods of acute disease and recovery. Relapses, caused 
by inflammation and formation of white matter lesions, usually do not last more than 
several months and patients can fully, or at least partially, recover. The clinical 
recovery results from the resolution of focal inflammation and edema, the recovery of 
demyelinated neurons and partial remyelination. Depending on the affected brain area, 
not all inflammation will result in a relapse as it is known from brain imaging studies. 
Therefore, depending on the area affected, lesions can be silent20.  
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In approximately two-thirds of the patients, the RR form converts into the SP form 
with accumulating neurological disabilities in the absence of attacks and newly forming 
inflammatory lesions. As no therapeutics is available to antagonize the progressing 
physical and cognitive damages, this transition has to be considered very problematic 
and current MS therapies mainly aim at the reduction of the number of relapses. 
About 15 % of all MS patients suffer from the rather aggressive PP form of MS 
which is characterized by a later clinical onset and a steadily accumulating disability 
without or with rare relapses. As for the SP form, new inflammatory demyelinating 
lesions are infrequent. However, changes and atrophy of the so called normal 
appearing white matter (NAWM) and the gray matter appear102, 176, 203. It seems that 
with increasing chronicity of the disease the inflammation in the CNS persists behind 
an intact BBB and is, therefore, not controlled by the peripheral immune system102. 
 
 
Figure 1: Clinical courses of RR and SP MS 
RR: relapsing remitting; SP: secondary progressive; EDSS: expanded disability status scale 
Clinical evolution of MS (EDSS, red line), brain atrophy (green line), overall tissue damage (blue line) and 
the frequency of inflammatory events (blue arrows) during the progression of RR and SP MS are shown 
(modified from176). 
1.1.2 Lesion pathology 
A complex pathogenic cascade is involved in initiating inflammation in the CNS with 
many different immune cells participating. To induce inflammation, potentially 
autoreactive CD4-positive T cells must be activated in the periphery, enter the brain 
and become reactivated by antigen-presenting cells in the CNS parenchyma73, 176. 
Usually, cellular migration into the CNS is prohibited by the BBB which is formed by 
tight junctions of endothelial cells79. To overcome this barrier, lymphocytes have to 
adhere to endothelial cells. This process is mediated by adhesion molecules such as 
very late antigen-4 (VLA-4) and lymphocyte function-associated antigen-1 (LFA-1), 
chemokine receptors and integrins. Natalizumab, a therapeutic antibody approved for 
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the treatment of MS, binds to VLA-4 and blocks the transmigration of lymphocytes into 
the CNS thereby inhibiting inflammation142. 
Subsequently to extravasation, CD4-positive T cells become reactivated by 
MHC class II-positive antigen-presenting cells which induces cell proliferation. Antigen-
presenting cells include perivascular macrophages, microglia and peripheral dendritic 
cells. Reactivation also leads to the release of a vast range of cytokines and 
chemokines and to the activation of astrocytes, microglia and endothelial cells79. This in 
turn allows the recruitment of other immune cells from the blood into the brain 
parenchyma including CD8-positive T cells, monocytes, B cells and mast cells. 
Damage of the myelin sheath, of oligodendrocytes and axons can already occur during 
this early inflammatory phase. 
The formation of the initial inflammatory lesion is mostly dependent on potentially 
autoreactive T cells, whereas, in subsequent events myelin degradation, 
oligodendrocyte and axonal damage is caused by a wide range of processes. These 
include: direct or antibody-mediated complement binding, direct lysis of axons by CD8-
positive T cells, phagocytosis of myelin as well as an increased release of radicals, 
proteases and glutamate139. The acute inflammation can last up to 14 days176. The 
lesion resolution involves the clearing of debris by macrophages, the activation of 
oligodendrocyte precursor cells (OPCs) and, in a minority of the lesions, the 
remyelination of demyelinated axons. However, the original myelin thickness cannot be 
restored and myelin produced by remyelination differs from the composition of mature 
myelin. Therefore, conduction velocity in these damaged areas is slower. In the long 
term, the cellular composition in the plaque areas can change heavily regarding cell 
types, formation of glial scars and cell number. An overview of the pathological 
processes involved in MS lesion formation is given in figure 2. 
According to the stage and cellular composition, white matter lesion can be 
classified as (1) demyelinated lesions, including active lesions and chronic active 
lesions, and (2) remyelinated lesions (figure 3).  
Active lesions are mostly found in patients with acute and RR MS and become rare 
at later stages or during the progressive phase of the disease101. Active lesions are 
completely demyelinated. In contrast-enhanced magnetic resonance imaging they are 
characterized by the uptake of gadolinium, indicating an opening of the BBB46. 
Furthermore, active lesions are characterized by infiltrating immune cells. 
Macrophages or microglia are dispersed throughout the lesion and commonly 
incorporate phagocytosed myelin, particularly in early active lesions204.  
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Figure 2: Model of pathological processes in MS lesions 
Processes during acute inflammation in MS. Contributing inflammatory and CNS resident cells as well as 
involved cytokines and chemokines are depicted (see text for details. Modified from176). 
Chronic active lesions are also completely demyelinated and are predominantly 
seen in patients with progressive MS. In contrast to active lesions, macrophages and 
microglia are located only at the edge of the lesion and myelin-laden macrophages or 
microglia are rare144.  
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During early stages of the disease, lesions become frequently remyelinated143. This 
process is believed to be mediated by OPCs which are recruited to the lesion site and 
ensheath demyelinated axons145. Remyelination can occur within the whole lesion 
area, resulting in so called “shadow plaques”. Shadow plaques are sharply demarcated 
areas exhibiting thin myelin with a reduced density. In a luxol fast blue (LFB) staining 
these areas appear as light blue spots (figure 3). More frequently, however, lesions do 
not become completely remyelinated but only at the peripheral margins of the plaque. 
At later stages and during the progressive phase of the disease remyelination becomes 
less frequent or is completely absent. Only little is known about the reasons for 
remyelination to fail. However, there are individual differences in patients. Not 
surprisingly, longer disease durations and older age at death were associated with a 
higher number of remyelinated lesions137. 
 
 
Figure 3: De- and remyelination in MS 
Luxol fast blue staining (LFB) of a post-mortem tissue of a patient with RR MS (autopsy, female, aged 
34 years, 156 months’ disease duration). Remyelinated shadow plaques (asterisks) and demyelinated 
lesion plaques (arrowheads) are visible (modified from111). 
1.2 ROLE OF ASTROCYTES IN MS 
Astrocytes are the most abundant cell type in the CNS and constitute nearly half of 
the brain cells in humans119. They have important functions in the trophic support of 
neurons and the maintenance of extracellular ion balance. Furthermore, astrocyte foot 
processes extend to capillaries in the CNS and biochemically support endothelial cells 
which form the BBB. Endothelial cells, astrocytes, the basal lamina and pericytes 
constitute the neurovascular unit which limits the molecular transport and cellular 
migration into the CNS79. Additionally, astrocytes play an important role in repair 
processes following any kind of brain injury. 
In response to injury, astrocytes leave their quiescent state. They become 
hypertrophic, start to proliferate and upregulate glial fibrillary acidic protein (GFAP), 
nestin and vimentin37. Moreover, they can migrate to the site of injury and, by 
continuously proliferating, form a glial scar (reactive astrogliosis). In MS, astrogliosis is 
a characteristic feature and astrocytes constitute the majority of cells in demyelinated 
6 Introduction 
lesions. The activation of astrocytes leads to a shift in the gene expression of adhesion 
molecules, antigen-presenting molecules, cytokines, growth factors and growth factor 
receptors as well as enzymes and enzyme inhibitors which influences the inflammatory 
response and cellular repair mechanisms37, 216. By interacting with neurons and other 
glial cells, astrocytes can additionally convey multifaceted functions during CNS injury 
and repair. It is difficult to separate the vast spectrum of astrocytic contributions in 
beneficial and detrimental as the outcome largely depends on the cellular composition 
of the lesion, the presence of other cytokines and the lesion stage. Established aspects 
of the astrocytic impact in lesion formation are briefly summarized in the following 
section. More comprehensive reviews on the role of astrocytes in lesion formation can 
be found elsewhere36, 37, 173, 216. 
1.2.1 Acute inflammation 
During acute inflammation, astrocytes can impact the integrity of the BBB, the 
migration and direction of immune cells into the CNS parenchyma, promote survival of 
immune cells and directly damage neuronal structures216 (figure 4, A). Astrocytes can 
mediate the migration of T cells by expression of vascular cell adhesion protein 1 
(VCAM1) which binds to VLA-4 expressed on lymphocytes71. Furthermore, astrocytes 
are known to express matrix metalloproteinases (MMPs) in response to CNS injury 
which might break open tight junctions and impact the integrity of the BBB53, 219. 
Besides increasing the expression of MMPs, astrocytes can also upregulate MMP 
modulators, such as tissue inhibitor of metalloproteinases 1 (TIMP1). These inhibitors 
can counteract MMP-mediated impacts and convey protective effects9. Having entered 
the brain parenchyma immune cells can be directed by astrocytes through expression 
of various chemokines and guidance molecules. Monocyte chemoattractant protein 1 
(MCP1)147, chemokine (C-X3-C motif) ligand 1 (CX3CL1)23 and chemokine (C-X-C 
motif) ligand 12 (CXCL12)75 were found to be upregulated in astrocytes in MS 
lesions40, 121 or experimental autoimmune encephalomyelitis (EAE)186, an animal model 
recapitulating important aspects of MS. Indirect recruitment can be accomplished by 
upregulation of chemokines and cytokines in response to autocrine stimulation of 
astrocytes with tumor necrosis factor α (TNFα) and lymphotoxin α (LTα). The survival 
and expansion of B cells as well as the production of IgG in MS lesion is stimulated by 
the B cell-activating factor BAFF, which was found to be strongly induced in astrocytes 
present in active and chronic active MS lesions98. However, astrocytes do not only 
pave the way for immune cell-mediated cell damage but can also directly cause 
damage in acute inflammation. An increase in nitric oxide and superoxide radicals, by 
an upregulation of inducible nitric oxide synthase (iNOS) expression in astrocytes 
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present in MS plaques51, is thought to directly harm oligodendrocytes and the myelin 
sheath. Axonal disruption that occurs in NAWM is attributed to reactive astrogliosis in 
the affected regions28, 52. In contrast to neuromyelitis optica (NMO), a loss or damage of 
astrocytes is not a feature of acute MS lesions. 
1.2.2 Lesion resolution 
Apart from the guidance of immune cells into brain parenchyma, astrocytes can 
also be involved in the recruitment of OPCs to the lesion plaque, in OPC differentiation 
and maturation and, therefore, participate in remyelination and lesion repair216 
(figure 4, B). The induction of interleukin 8 (IL8), CXCL1 and CXCL10 was observed in 
reactive astrocytes surrounding lesions136. The corresponding receptors (CXCR1, 2 
and 3) were found increasingly expressed on oligodendrocytes in MS136. Moreover, 
semaphorins 3A and 3F (SEMA3A, SEMA3F) were shown to affect OPC migration and 
expression was increased in astrocytes surrounding active lesions215. SEMA3A acts as 
a repulsive and SEMA3F as an attractive signal215.  
Following migration, both oligodendrocyte proliferation as well as differentiation can 
be supported by astrocytes. Ciliary neurotrophic factor (CNTF), e.g., promotes OPC 
survival6 and maturation into a myelinating phenotype181. Furthermore, it is an 
upstream regulator of fibroblast growth factor 2 (FGF2)6 which is known to be a 
mitogen for OPCs19. Further molecules which were attributed to be involved in 
oligodendrocyte differentiation are: Adenosine triphosphate (ATP)81, its degradation 
product adenosine182, insulin-like growth factor 1 (IGF1)65, 77, interleukin 1β (IL1β)116, 
interleukin 11 (IL11)225 and leukemia inhibitory factor (LIF)81 which were shown to 
directly (adenosine, IGF1, IL11, LIF) or indirectly (ATP, IL1β) stimulate OPC 
differentiation and maturation. Additionally, transforming growth factor β (TGFβ), in the 
presence of platelet-derived growth factor (PDGF), also reduces proliferation and 
enhances differentiation in vitro120. On the other hand, TGFβ promotes Jagged1 
production in astrocytes which can bind to Notch1 on oligodendrocytes and retains 
them in a premature state86 (figure 4, A). Even the role of the glial scar in remyelination 
is ambivalent. Mostly, OPCs are found at the rim of demyelinated lesions and 
remyelination can be supported by above-mentioned mechanisms. However, as 
astrogliosis might impair migration of OPCs, they are barely found in the lesion 
center17, 37.  
The outcome of MS pathology and the degree of neuronal damage is widely 
influenced by the astrocyte response and their interaction with other cell types. 
Therefore, understanding astrocyte-mediated functions and the impact of astrogliosis at 
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different lesion stages is crucial to regulate tissue damage and repair in MS and makes 
astrogliosis a potential therapeutic target. 
 
 
Figure 4: Putative effects of astrocytes in MS 
(A) Acute inflammation. Astrocytes are involved in T cell extravasation, activation and in the recruitment of 
immune cells into the CNS parenchyma. Thereby, they support the immune attack, demyelination and 
degeneration of axons. Furthermore, astrocytes can indirectly damage myelin and oligodendrocytes and 
inhibit OPC differentiation. (B) Lesion resolution. Astrocytes can attract OPCs to the lesion site, support 
their proliferation, survival and differentiation. Moreover, protective effects are conveyed by secretion of 
growth factors and glutamate uptake. Expression of TIMPs might restore integrity of the BBB (see text for 
details. Modified from216). 
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1.3 GENE EXPRESSION PROFILING IN MS 
Gene expression profiling and microarray based analysis enables the detection of 
thousands of regulated genes in a single RNA sample. This offers a wide range of 
possibilities to unravel pathways, molecular mechanisms and biological functions 
involved in the pathology of MS. Gene expression profiling in MS was performed in a 
broad range of studies mainly using peripheral blood mononuclear cells or brain tissue 
isolated from MS patients (reviewed in55). The application of gene expression profiling 
in peripheral blood mononuclear cells has revealed to be particularly useful to study the 
impact of different therapies in MS patients, as changes in peripheral leukocytes might 
precede changes in the CNS55. Studies using MS brain tissue, often have to struggle 
with poor RNA quality and a small number of samples. Furthermore, as most samples 
are derived from post-mortem tissue, analysis mainly represents the late progressive 
phase of the disease. Also, a proper characterization of lesions and lesion stage is 
mandatory for the interpretability of the results. Nonetheless, using gene expression 
profiling, important and interesting insights in MS lesion environment, involved 
molecular mechanisms and pathways could be gained. 
In a previous study performed in our laboratory (Mohan et al., unpublished data), 
different MS lesions were macro-dissected, including remyelinated lesions, 
demyelinated lesions as well as active lesions. Gene expression was analyzed using a 
low density array and compared to the gene expression of control brain white matter 
and NAWM surrounding the plaque areas. In this analysis, FGF1, an abundant factor in 
human brain (figure 5, A) appeared to be upregulated in remyelinated areas (figure 5, B 
and C). This suggests a role of FGF1 in the regulation of MS pathology. These findings 
provided the basis for subsequent experiments aiming at the identification of FGF1-
mediated mechanisms in MS pathology. FGF1 was found to promote myelination in an 
in vitro myelinating culture system as well as remyelination in a slice culture model 
(collaboration with T. Kuhlmann; Mohan et al., in preparation). 
1.4 FIBROBLAST GROWTH FACTORS 
FGFs convey a multitude of functions. During development, they are key players in 
tissue patterning and organogenesis, whereas, during adulthood they are involved in 
angiogenesis and repair in a plurality of mammalian tissues. The family of FGFs 
comprises 22 members. FGF1-FGF10 and FGF16-FGF23 can be further grouped into 
six subfamilies (FGF subfamilies 1; 4; 7; 8; 9 and 19) depending on their phylogeny 
and differences in sequence (figure 6)84. FGF11-FGF14 are factors highly homologue 
to FGFs but cannot activate the fibroblast growth factor receptors (FGFRs). They 
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constitute the FGF subfamily 11 (figure 6). FGF15 is the mouse homologue to human 
FGF19.  
All FGFs, except of those belonging to the FGF1 and FGF9 subfamilies, do have 
signal peptides for secretion. Members of the FGF9 subfamily, although lacking a 
signal sequence, are secreted by the endoplasmic reticulum-Golgi pathway153. FGF1 
and FGF2, in contrast, are secreted independently of the endoplasmic reticulum. 
Although the exact mechanism is not yet fully elucidated, they are probably released 
upon cell damage66, 126. All FGFs have a homologous core region, composed of 12 
antiparallel β-strands (β1-β12) and variant N- and C-termini. The high affinity for 
proteoglycans, heparan sulfate and heparin is characteristic for FGFs. It can stabilize 
the interaction with the receptors72, 220, increase the stimulation efficiency168 and induce 
oligomerization178. Therefore, the interaction with heparan sulfate proteoglycan can be 
essential for the activation of FGFRs (figure 7). The heparan sulfate proteoglycan 
binding site is composed of the β1-β2 loop and regions of β10 and β1226. 
 
 
Figure 5: Enhanced expression of FGF1 in remyelinated plaques 
CWM: control white matter; De: demyelinated; Re: remyelinated; AL: active lesion; GM: gray matter 
(A) Relative RNA levels of factors potentially involved in oligodendrocyte regulation (% GAPDH, 
housekeeping gene). These include PDGFs, FGFs, semaphorins, chemokines, members of the IL6 family, 
IGFs and other factors with implications in the regulation of oligodendrocytes (CTGF, VEGF, HGF, IL11, 
LINGO1). FGF1 is an abundant factor in human brain (arrow). (B) The relative FGF1 level (% GAPDH, 
housekeeping gene) was elevated in remyelinated lesions compared to CWM, demyelinated and active 
lesions. (C) LFB/HE staining of a representative MS lesion. Marked areas were macro-dissected (left) and 
the corresponding relative FGF1 level in re- and demyelinated areas (right) was determined by RT-qPCR 
(modified from Mohan at el., in preparation). 
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1.4.1 Fibroblast growth factor receptors 
FGFs act by binding to FGFRs which belong to the tyrosine kinase receptor family. 
FGFRs have three extracellular immunoglobulin-like domains (domain I–domain III), a 
single pass transmembrane domain and an intracellular tyrosine kinase domain. It has 
been shown that domains II and III are necessary and sufficient for FGF binding. Four 
FGFRs have been identified (FGFR1-FGFR4) exhibiting a differential FGF-dependent 
binding affinity. The functional diversity of the FGF signaling can be further increased 
by alternative splicing of the domain III in FGFR1, FGFR2, and FGFR3 which impacts 
the FGF-FGFR binding specificity214. FGF1 is a universal ligand which can equally bind 
and activate all FGFRs and splicing variants and is, therefore, an exception of this rule. 
Furthermore, in some pathological conditions, such as cancer, FGF binding 
specificities can be abrogated74.  
Upon FGF binding, dimerization of FGFRs is initiated and followed by activation 
through intracellular autophosphorylation at a number of tyrosine residues (figure 7). 
Main intracellular substrates of activated FGFRs are phospholipase C (PLC) and FGFR 
substrate 2 (FRS2)26 which are recruited to the activated receptors, become 
phosphorylated and initiate associated downstream pathways. Beside the activation of 
the PLC pathways, the phosphorylation of FRS2 results in activation of the 
Ras/mitogen activated protein kinase (MAPK) pathway as well as the phosphoinositide-
3-kinase (PI3K)-Akt signaling pathway50. 
 
 
Figure 6: FGF subfamilies 
Evolutionary relationship of the human FGF family. Branch length is proportional to the evolutionary 
distance between each gene (modified from84). 
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1.4.2 FGFRs in the CNS 
The growth of several brain structures during development is controlled by 
differential FGF expression. In adults, FGFs regulate neurogenesis and axonal growth, 
they are implicated in the maintenance and repair of neural tissue and convey 
neuroprotective functions. Furthermore, the effects of FGFs were associated with 
learning and memory153. 
FGFR1, FGFR2 and FGFR3 are expressed by different cell types and in different 
areas of the adult CNS. FGFR4 is largely expressed during development and almost 
absent in the adult brain153. Regional differences in FGFR1-FGFR3 expression were 
observed. High levels of FGFR1-FGFR3 expression can be found in diencephalon and 
telencephalon, whereas, these receptors exhibit moderate expression levels in the 
metencephalon. Low expression is found in the myelencephalon27. Also, differential 
expression can be observed in different CNS cell types. Expression of FGFR1 is mostly 
localized to neurons221 but can also be detected in astrocytes189. Furthermore, glia cells 
do express FGFR2 and FGFR313, 221. 
 
 
Figure 7: FGF receptor complex 
Upon FGF binding, a complex of two FGFs, two FGFRs and heparan sulfate proteoglycan is formed. 
Autophosphorylation of tyrosine residues results in the activation of different downstream signaling 




FGF1 (alternatively named acidic FGF) is a paracrine FGF ligand. Due to its high 
affinity for heparan sulfate proteoglycan, FGF1 acts in a localized manner close to the 
expressing cells26. Together with FGF2, FGF1 was the first FGF isolated from bovine 
brain and was named for its proliferative activity on fibroblasts194. As FGF1-/- mice are 
fully viable and fertile, its physiological role remains unclear. However, it was 
demonstrated to be involved in the maintenance of blood pressure48 and seems to play 
a role in the regulation of adipogenesis80. Furthermore, it is thought to modulate 
organogenesis as it acts as a mitogen for mesoderm and neuroectoderm-derived cells 
and functions in angiogenesis. 
In the CNS, FGF1 is widely expressed during the development and still present in 
adults with varying expression levels in different areas of the nervous system56. It is 
predominantly expressed by neurons24, 57, 183 but can also be found in glial cells83, 114. In 
normal brain it seems to be implicated in learning processes and memory, as it was 
shown to impact long-term potentiation161. Furthermore, FGF1 acts as a potent mitogen 
for glial cells59, 159, 163. A role for FGF1 in CNS pathology has also been described. 
FGF1 was found to convey neuroprotective effects as it prevents neuronal death in 
seizure-associated brain damage49 and ischemia47, 162. 
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2 OBJECTIVES AND STRATEGY 
MS is an inflammatory demyelinating disease of the CNS in which remyelination is 
often limited or absent. A better understanding of the complex interactions in the MS 
lesion environment and a more detailed knowledge of features conveyed by involved 
factors could provide the basis for therapy improvements. In a previous work, FGF1 
was identified as an abundant factor in MS brains which was particularly induced in 
remyelinated lesions (Mohan et al., in preparation). 
The objective of the present study was to provide further insight into potential roles 
of FGF1 in MS lesion development. Therefore, the following strategy was used: 
First, a published58 in vitro myelinating culture system was established in our 
laboratory and a rapid and easy to use method for the quantification of changes in 
myelination and axonal density was developed. This in vitro myelinating culture was 
subsequently used to investigate effects of FGF1 on myelination (independent study). 
Secondly, the effects of FGF1 on FGFR-expressing primary human astrocytes in 
cell culture were analyzed. Changes in FGF1-mediated gene expression were 
measured using an Affymetrix GeneChip® Human Gene 1.0 ST array and alterations in 
the secretion of glycosylated proteins were determined by application of a recently 
developed secretome approach99. 
Thirdly, FGF1 expression was localized to different cell types in control brain as 
well as MS lesions by IHC. 
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3 MATERIALS AND METHODS 
3.1 MATERIALS 
3.1.1 Antibodies 
Table 1: Primary and secondary antibodies 
3.1.1.a Antibody-mediated complement dependent effects in rat in vitro 
myelinating cultures 





Isotype control - - Mouse IgG1 1 1:100 Invitrogen, Carlsbad, USA 
Isotype control - - Mouse IgG2a 1 1:100 Invitrogen 
MOG - Z2 Mouse IgG2a 0.65 1:65 In-house hybridoma138 
MOG - 8-18C5 Mouse IgG1 2.33 1:233 In-house hybridoma108 
Pan-neurofascin - A12/18.1 Mouse IgG2a 1.4 1:140 In-house hybridoma117 
3.1.1.b Immunocytochemistry 
MOG - Z2 Mouse IgG2a 0.65 1:65 In-house hybridoma138 
Mouse IgG1 Alexa 568 - Goat IgG 2 1:2000 Invitrogen 
Mouse IgG2a Alexa 488 - Goat IgG 2 1:2000 Invitrogen 
Neurofilament - SMI-310 Mouse IgG1 Ascites 1:1000 abcam, Cambridge, UK 
3.1.1.c Immunohistochemistry (IHC): primary anti-human antibodies 
CD20 - EP459Y Rabbit Superna
tant 
1:50 Epitomics, Burlingame, 
USA 
CD3 - CD3-12 Rat IgG1 1 1:100 AbD Serotec, Kidlington, 
UK 
CD68 - PG-M1 Mouse IgG3 - 1:1 DAKO, Glostrup, 
Denmark 
FGF1 - 2E12 Mouse IgG1 1 1:50 abcam 
GFAP - - Rabbit IgG 2.9 1:500 DAKO 
Iba-1 - - Rabbit IgG 0.5 1:333 Wako, Neuss, Germany 
Isotype control - 107.3 Mouse IgG1 0.5 1:100 BD, Heidelberg, Germany 
Isotype control - - Rat IgG1 1 1:100 abcam 
Isotype control - - Rabbit IgG 15 1:5000 DAKO 
KiM1P - - Mouse IgG - 1:1000 Radzun et al.146 
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3.1.1.d IHC: secondary antibodies 
Mouse IgG1 Biotin A85-1 Rat IgG1 0.5 1:250 BD 
Mouse IgG2a Alexa 488 - Goat 2 1:1000 Invitrogen 
Mouse IgG3 Alexa 488 - Goat 2 1:1000 Invitrogen 
Rabbit IgG Alexa 488 - Goat 2 1:1000 Invitrogen 
Rat IgG Alexa 488 - Goat 2 1:1000 Invitrogen 
3.1.1.e IHC: streptavidin constructs 
Streptavidin Alexa 568 - - 2 1:1000 Invitrogen 
Streptavidin Peroxidase - - 1 1:1000 Jackson IR, Pennsylvania, 
USA 
3.1.1.f Flow cytometry: anti-human antibodies 
CD3 RPE UCHT1 Mouse IgG1 - 1:10 DAKO 
CD20 PerCP L27 Mouse IgG1 - 1:5 BD 
3.1.2 Quantitative PCR assays 
Table 2: Quantitative PCR (qPCR) assays 
Gene name qPCR assay Detection Company 
COL1A1 Hs00164004_m1 FAM-TAMRA Applied Biosystems, Foster City, USA 
COL1A2 Hs.PT.56a.26714610 FAM-Iowa Black® FQ IDT, Coralville, USA 
COL4A2 Hs00300500_m1 FAM-TAMRA Applied Biosystems 
COL5A2 Hs.PT.56a.24969881 FAM-Iowa Black® FQ IDT 
EGR1 Hs00152928_m1 FAM-TAMRA Applied Biosystems 
FGFR1 Hs.PT.51.20650860 FAM-Iowa Black® FQ IDT 
FGFR2 Hs00240792_m1 FAM-TAMRA Applied Biosystems 
FGFR3 Hs00179829_m1 FAM-TAMRA Applied Biosystems 
FGFR4 Hs.PT.51.19306610 FAM-Iowa Black® FQ IDT 
HMOX1 Hs01110250_m1 FAM-TAMRA Applied Biosystems 
IL8 Hs00174103_m1 FAM-TAMRA Applied Biosystems 
KCNN4 Hs00158470_m1 FAM-TAMRA Applied Biosystems 
LIF Hs00171455_m1 FAM-TAMRA Applied Biosystems 
MMP1 Hs.PT.56a.38692586 FAM-Iowa Black® FQ IDT 
MMP9 Hs00234579_m1 FAM-TAMRA Applied Biosystems 
NT5E Hs.PT.56a.21216674 FAM-Iowa Black® FQ IDT 
PPIA 4326316E VIC-MGB Applied Biosystems 
PTX3 Hs00173615_m1 FAM-TAMRA Applied Biosystems 
SPHK1 Hs00184211_m1 FAM-TAMRA Applied Biosystems 
TIMP1 Hs.PT.56a.27632928 FAM-Iowa Black® FQ IDT 
  
Materials and Methods 17 
3.1.3 Enzyme-linked immunosorbent assay 
Table 3: Kits 
Target protein Target species Product number Company 
IL11 Human DY218 R&D Systems 
LIF Human BMS242MST Bender MedSystems, Vienna, Austria 
MMP9 Human DY911 R&D Systems 
MMP9 activity assay Human QZBmmp9H QuickZyme, Leiden, Netherland 
3.1.4 In vitro myelinating culture 
3.1.4.a Neurosphere-derived astrocytes 
Table 4: Growth factors and medium supplements 
Glucose 30 % glucose (w/v) in H2O, filtered (0.22 
µm) 
Sigma-Aldrich, Taufkirchen, Germany 
NaHCO3 7.5 % NaHCO3 (w/v) in H2O, filtered 
(0.22 µm) 
Sigma-Aldrich 
Putrescine 966 µg/ml putrescine in H2O, filtered 
(0.22 µm) 
Sigma-Aldrich 
Sodium selenite 520 µg/ml sodium selenite in H2O, 
filtered (0.22 µm) 
Sigma-Aldrich 
Progesterone 630 µg/ml progesterone in 95 % ethanol Sigma-Aldrich 
Epidermal growth factor (EGF), 
murine 
0.5 mg/ml EGF in 0.1% BSA/PBS PeproTech, Rocky Hill, USA 
 
Table 5: 10x Hormone supplement for neurosphere medium 
DMEM 42.5 % Invitrogen 
F12 42.5 % Invitrogen 
30 % Glucose 0.6 % Sigma-Aldrich 
7.5 % NaHCO3 0.1125 % Sigma-Aldrich 
HEPES 5 mM Invitrogen 
Transferrin 1 mg/ml Sigma-Aldrich 
Insulin solution, human, # I9278 240 µg/ml Sigma-Aldrich 
Putrescine (966 µg/ml) 96.6 µg/ml Sigma-Aldrich 
Sodium selenite (520 µg/ml) 52 ng/ml Sigma-Aldrich 
Progesterone (630 µg/ml) 6.3 ng/ml Sigma-Aldrich 
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Table 6: Neurosphere medium 
DMEM 42 % Invitrogen 
F12 42 % Invitrogen 
10x Hormone supplement 10 % table 5 
30 % Glucose 0.6 % Sigma-Aldrich 
7.5 % NaHCO3 0.1125 % Sigma-Aldrich 
1 M HEPES 5 mM Invitrogen 
200 mM L-Glutamine  2 mM PAN Biotech, Aidenbach, Germany 
 
Table 7: Rat astrocyte medium 
DMEM 89 % Invitrogen 
Fetal calf serum (FCS) 10 % Biochrom, Berlin, Germany 
Penicillin-streptomycin 1 % Invitrogen 
3.1.4.b Spinal cord culture 
Table 8: Medium supplements 
Biotin, stock solution 1 mg/ml biotin in 1M NaOH Sigma-Aldrich 
Biotin, working solution Biotin stock solution diluted to 10 µg/ml 
with H2O, filtered (0.22 µm) 
Sigma-Aldrich 
Hydrocortisone 100 µM hydrocortisone in H2O, filtered 
(0.22 µm) 
Sigma-Aldrich 




Table 9: Digestive enzymes 
Collagenase 1 % (w/v) collagenase in Leibovitz L-15, 
filtered (0.22 µm) 
Both Invitrogen 
Trypsin 2.5 % (w/v) trypsin in HBSS without Ca2+ 




Table 10: Soybean trypsin inhibitor solution 
BSA, fraction V 3 mg/ml Sigma-Aldrich 
Deoxyribonuclease I, bovine 
pancreas 
40 µg/ml Sigma-Aldrich 
Trypsin inhibitor, soybean 520 µg/ml Sigma-Aldrich 
All components dissolved in Leibovitz L-15 medium, filtered (0.22 µm) 
 
Table 11: Plating medium (PM) 
DMEM (4,5 g/l glucose) 49 % Invitrogen 
Horse serum 25 % Sigma-Aldrich 
HBSS  25 % Invitrogen 
200 mM L-Glutamine 2 mM PAN Biotech 
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Table 12: Differentiation medium (DM) 
DMEM (4.5 g/l glucose) 99.4 % Invitrogen 
Biotin, working solution 10 ng/ml table 8 
Hydrocortisone, 100 µM 18.1 ng/ml table 8 
N1 medium supplement 5 µl/ml Sigma-Aldrich 
 
Table 13: Differentiation medium with insulin (DM/I) 
DMEM (4.5 g/l glucose) 97.4 % Invitrogen 
Biotin, working solution 10 ng/ml table 8 
Hydrocortisone, 100 µM 18.1 ng/ml table 8 
Insulin, 0.5 mg/ml 10 µg/ml table 8 
N1 medium supplement 5 µl/ml Sigma-Aldrich 
3.1.5 Tissue specimen 
Table 14: Formalin fixed, paraffin embedded (FFPE) tissue specimen 
3.1.5.a Post-mortem brain tissue of MS patients 
Lesion type Age Gender Sample ID Source 
Active 53 f Nbb 03-130 #9.10 Netherlands Brain Bank (Amsterdam, Netherland) 
Active (chronic) 66 m Nbb 06-054 # 2 Netherlands Brain Bank 
Remyelinated 54 f A136/09 34 Dr. A. Junker (UMG, Göttingen, Germany) 
Remyelinated 52 f A212/07 Dr. A. Junker 
Remyelinated 59 m Nbb 03-074 # 1 Netherlands Brain Bank 
Remyelinated 59 m Nbb 03-074 # 2 Netherlands Brain Bank 
Remyelinated/active 59 m Nbb 03-074 # 3 Netherlands Brain Bank 
Remyelinated 66 m Nbb 06-054 # 6 Netherlands Brain Bank 
Remyelinated 70 f Nbb 06-077 #3 Netherlands Brain Bank 
Remyelinated 62 m T8/00-17 Dr. A. Junker 
3.1.5.b Post-mortem control tissue of accident victims 
Control (cortex) 18 m 14668-07-17 Klinikum Großhadern (LMU, Munich, Germany) 
Control (cortex) 16 m 14670-07-26c Klinikum Großhadern  
Control (brainstem) 66 f 151460-07-18 Klinikum Großhadern  
3.1.6 Buffers and solutions  
Table 15: Tris-EDTA buffer 
Trizma® Base 10 mM Sigma-Aldrich 
Titriplex® 1 mM Merck, Darmstadt, Germany 
Tween-20 0.05 % (v/v) Bio-Rad, Hercules, USA 
pH was adjusted to 9.0 
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Table 16: Luxol fast blue (LFB) solution 
Solvent Blue 38 10 mg/ml Sigma-Aldrich 
Acetic acid, glacial 5 µl/ml Sigma-Aldrich 
Ethanol 95 % (v/v) in H2O Sigma-Aldrich 
Filtered (0.22 µm) 
 
Table 17: Flow cytometry buffer 
BSA 1 % Sigma-Aldrich 
Sodium azide 0.1 % Sigma-Aldrich 
In PBS, filtered (0.22 µm) 
3.2 METHODS 
3.2.1 In vitro myelinating culture 
All incubation steps were performed in a humidified incubator (Heraeus, 
Langenselbold, Germany) at 37°C, 5 % and 7 % CO2, respectively.  
3.2.1.a Animals 
Wistar rats. All animals used in this study were obtained from the animal facility at 
the Max Planck Institutes of Biochemistry and Neurobiology. 
3.2.1.b Neurosphere-derived astrocytes  
Neurosphere preparation. The method is based on work published by Reynolds 
and Weiss154, 155 and was performed as described174, 195 with some modifications. Every 
step with exception of the dissection was performed under sterile conditions. Briefly, 
the corpus striatum from P1 Wistar rat brains was dissected and a maximum of 
4 striata per bijoux was collected in 1-2 ml Leibovitz L-15 medium (Sigma-Aldrich). A 
single cell suspension was obtained using a Pasteur pipette, cells were pelleted by 
centrifugation (140 g, 5 min) and subsequently resuspended in 20 ml neurosphere 
medium (table 6). Cells were transferred to a T75 cm3 cell culture flask (BD) and the 
medium was supplemented with 20 ng/ml EGF. Cells were incubated at 37°C, 5 % CO2 
and supplemented with 5 ml medium and 20 ng/ml EGF every three days. After seven 
days neurospheres were large enough to be plated to form astrocytes. 
Poly-L lysine coating. Cover glasses (13 mm diameter; ThermoFisher, Waltham, 
USA) were coated with 13.2 µg/ml poly-L-lysine in H2O (Sigma-Aldrich) for 2 h at 37°C, 
washed three times with H2O and placed in a 24-well plate (Corning Incorporated, 
Corning, USA). 
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Astrocyte monolayer generation. Neurospheres were differentiated into astrocytes 
as described in detail before with minor alterations174, 195. Briefly, neurospheres were 
pelleted by centrifugation (140 g, 5 min, 9°C), supernatant was removed, cells were 
triturated with a Pasteur pipette in 1 ml rat astrocyte medium (table 7) and 
subsequently filtered using a 44 µm cell strainer (BD). Single cells obtained from one 
T75 cm3 cell culture flask were filled up to a total volume of 12 ml with rat astrocyte 
medium, were distributed equally on a 24-well plate endowed with poly-L lysine coated 
coverslips (500 µl/well) and subsequently filled up to 1 ml/well with rat astrocyte 
medium. Cells were incubated at 37°C, 5 % CO2 changing 50 % of the media every 
three days. After 7 to 10 days, astrocytes formed a confluent monolayer on which 
spinal cord cultures were plated to form in vitro myelinating cultures. 
3.2.1.c Spinal cord culture 
Spinal cord cultures from embryonic Wistar rats were prepared as previously 
described174 with some modifications. 
Spinal cord dissection. Wistar rats were kill time-mated with the day of plugging 
denoted as E0.5. Embryos were used at day E15.5. After killing with an overdose of 
CO2, the gravid uterus was removed from the mother and placed into ice cold HBSS 
(Invitrogen). Embryos were removed from embryonic sacs and decapitated without 
removal of the cervical flexure. For dissection of the spinal cord, the skin was removed 
and after exposure, the spinal cord was carefully taken out. Meninges were stripped, a 
maximum of 7 spinal cords was placed in 1 ml fresh, ice cold HBSS and gently 
triturated using a Pasteur glass pipette. 
Spinal cord single cell suspension. Trypsin and collagenase (table 9) were added to 
the minced spinal cords at a final concentration of 0.25 % and 0.1 %, respectively and 
were incubated at 37°C for 15 min. Enzymatic digestion was stopped by the addition of 
two volumes soybean trypsin inhibitor solution (table 10) and digested tissue was 
pelleted by centrifugation (160 g, 5 min, 4°C). The supernatant was discarded, the cell 
pellet was resuspended in PM (table 11) and the cell number was determined using a 
Neubauer hemocytometer (Paul Marienfeld, Lauda-Königshofen, Germany). The cell 
suspension was diluted to a density of 3x106 cells/ml with PM (table 11). 
Plating on astrocytes. Astrocytes, homogeneously grown on cover glasses, were 
transferred from 24-well plates to 35 mm cell culture-treated culture dishes (Corning 
Incorporated) with a maximum of three cover glasses per 35 mm culture dish. Spinal 
cord single cell suspension was added on top of the astrocyte monolayer with a density 
of 1.5x105 cells/cover glass and incubated at 37°C, 7 % CO2 for 20 min. After spinal 
cord single cells attached to the astrocytes, medium was topped up with 350 µl/dish 
PM and 500 µl/dish DM/I (table 11, table 13) to a total volume of 1 ml.  
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In vitro myelinating culture. The spinal cord cultures were incubated at 37°C, 
7 % CO2 50 % of the medium was replaced by fresh DM/I (table 13) every three days 
until day 12 in vitro. From day 12 to day 26, insulin was omitted from the culture 
medium to stimulate myelination. Therefore, DM (table 12) was used to replace 50 % of 
the medium every three days.  
3.2.1.d Antibody/complement treatment 
Antibody-mediated complement dependent demyelination and the induction of 
axonal loss in in vitro myelinating cultures were described in detail before 58 and the 
method was applied with modifications. Briefly, at day 26 in vitro the medium was 
completely removed and 500 µl/dish DM supplemented with 2.5 % baby rabbit 
complement (Cederlane, Burlington, Canada) as well as 10 µg/ml of the respective 
antibody (table 1) was added to the in vitro myelinating cultures and incubated for 
90 min (37°C, 7 % CO2). Subsequently, medium was completely removed and cells 
were washed twice with PBS (Invitrogen). They were fixed by addition of 4 % PFA 
(Merck) in PBS (15 min, room temperature) and washed three times with PBS. 
Additionally, control cultures were treated with either (1) complement alone, 
(2) antibody with heat-inactivated complement (56°C, 30 min) or (3) the corresponding 
isotype controls (table 1) in combination with complement. Three independent cover 
glasses were analyzed for each condition. 
3.2.2 Immunocytochemistry 
All images were acquired on an inverted AxioVert200M fluorescent microscope 
(Carl Zeiss, Oberkochen, Germany) and processed using MetaMorph software 
version 7.7 (Molecular Devices, Sunnyvale, USA) and ImageJ software (NIH, 
Bethesda, USA). 
Fluorescence immunocytochemistry. For fluorescence staining of the PFA fixed 
in vitro myelinating cultures, the cover glasses were carefully transferred to a 24-well 
plate. For the staining of intracellular targets, the cells were permeabilized with 
0.5 % TritonX-100 in 1 % BSA/PBS (Carl Roth, Karlsruhe, Germany; Sigma-Aldrich) for 
10 min and washed once with PBS. Unspecific antibody binding was blocked by 
incubation with 10 % FCS (Biochrom) in 1 % BSA/PBS for 30 min. Primary antibodies 
in 1 % BSA/PBS were either incubated over night at 4°C or 2 h at room temperature. 
Cells were washed three times and appropriate fluorochrome-conjugated secondary 
antibodies (in 1 % BSA/PBS) were applied for 20 min in the dark, at room temperature. 
For visualization of the nuclei, 1 µg/ml DAPI (Carl Roth) was added and incubated for 
additional 10 min in the dark. After three final washes, cover glasses were mounted 
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with Fluoromount G (SouthernBiotech, Birmingham, USA) upside down on microscope 
slides (ThermoFisher).  
Image acquisition. For quantification, images were acquired at 10x magnification. 
In vitro myelinating cultures were characterized by determination of the axonal density, 
the degree of myelination and the loss of axons and myelin upon treatment with 
antibodies and complement. These basic characteristics were determined from at least 
10 images acquired from three independent cover glasses.  
Quantification. MetaMorph Software Version 7.7 was used for quantification of the 
axonal density as well as for the determination of myelination and demyelination. 
Briefly, 16-bit grayscale images were acquired, brightness and threshold were adjusted 
consistently and the images were equally transformed into binary pictures. Binary 
pictures were corrected using “shape factor” (defined as 4πA/P2) and area analysis as 
criteria. All modifications were automatically and equally applied to all images using the 
MetaMorph “journal loop” tool. The axonal density was calculated by dividing the pixel 
values of the corrected binary picture by the pixel values of the total image area. 
Likewise, the myelin density was calculated by dividing the pixel values determined for 
the myelin (corrected binary) by the pixel values determined for axons (corrected 
binary). 
3.2.3 Primary human astrocytes 
All incubations steps were performed in a humidified incubator (Heraeus) at 37°C 
and 10 % CO2. 
Routine cell culture. Human astrocytes of embryonic origin were obtained from the 
laboratory of Francesca Aloisi7 (ISS, Rome, Italy) and stored in liquid nitrogen until 
needed. Human astrocytes derived from two different embryos were used for 
independent experiments. For routine cell culture DMEM (Invitrogen) was 
supplemented with 10 % FCS (Biochrom) and 1 % penicillin-streptomycin (Invitrogen). 
For splitting, cells were rinsed with PBS (Invitrogen) and detached by incubation with 
Trypsin-EDTA (PAA Laboratories, Pasching, Austria) for 10 to 15 min at 37°C. Cells 
were pelleted by centrifugation at 160 g for 10 min at 4°C, resuspended in DMEM and 
plated as needed. Human astrocytes were used at passages 2-6. 
FGF1 stimulation. For stimulation of primary human astrocytes with FGF1, cells 
were grown to confluence in 24-well plates (Corning Incorporated) with the following 
exceptions: For the transcriptome microarray analysis, cells were grown in 6-well plates 
(Corning Incorporated). For the secretome analysis primary human astrocytes were 
grown in T175 cm3 cell culture flasks (BD). Medium was changed to serum-free 
Panserin 401 (PAN Biotech) supplemented with 1 % penicillin-streptomycin 24 h prior 
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to stimulation. Unless stated otherwise 10 ng/ml recombinant human FGF1 
(R&D Systems) and 5 U/ml Heparin-Natrium-25000-ratiopharm® (ratiopharm, Ulm, 
Germany) in Panserin 401 were used for stimulation of primary human astrocytes for 
the indicated time periods. Control samples were incubated with 5 U/ml Heparin-
Natrium-25000-ratiopharm® in Panserin 401. 
3.2.4 RNA techniques 
RNA extraction. Total RNA from primary human astrocytes or purified lymphocytes 
(3.2.8) was extracted using the RNeasy Mini Kit (Qiagen, Venlo, Netherland) following 
the instructions provided by the manufacturer. Briefly, cells were lysed in an 
appropriate amount of RLT buffer supplemented with 10 µl/ml 2-mercaptoethanol 
(Sigma-Aldrich). One volume of 70 % ethanol (Sigma-Aldrich) was added and the total 
RNA was purified using the silica-membrane-equipped spin columns included in the kit. 
Purified RNA was eluted with 20 to 30 µl ribonuclease free water (Invitrogen).  
Reverse transcription (RT). RNA concentration and purity was estimated using 
NanoDrop ND-1000 (PeqLab, Erlangen, Germany) and 200 to 500 ng of RNA were 
diluted with ribonuclease free water to a total volume of 10 µl/reaction. cDNA was 
generated using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems) according to the manufacturer instructions with a final volume of 
20 µl/reaction.  
Quantitative PCR (qPCR). 10 to 25 ng cDNA per reaction were applied (determined 
by means of the total RNA concentration). Either TaqMan® assays (Applied 
Biosystems) or PrimeTime® qPCR assays (IDT), listed in table 2, were used in 
combination with the TaqMan® PCR Core Reagent kit (Applied Biosystems) according 
to manufacturer instructions. Samples were run in MicroAmp™ Optical 96-well reaction 
plates (Applied Biosystems) in a 7900HT Fast Real-Time PCR System (Applied 
Biosystems). Data were analyzed using SDSv2.3 software (Applied Biosystems). 
3.2.5 Transcriptome microarray analysis 
FGF1 stimulation of primary human astrocytes. Primary human astrocytes were 
incubated with either 5 U/ml heparin or 10 ng/ml FGF1 and 5 U/ml heparin for 8 h and 
24 h, respectively. The experiment was performed in triplicates for each condition and 
time point, resulting in a total of 12 independent samples which were used for the 
transcriptome microarray analysis. RNA was purified as described (3.2.4) and samples 
were further processed by IMGM laboratories (Martinsried, Germany) as briefly 
summarized in the following paragraph. 
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Affymetrix GeneChip® Human Gene 1.0 ST array. Determination of RNA 
concentration, purity (NanoDrop ND-1000; PeqLab) and integrity (RNA 6000 Nano 
LabChip kits and 2100 Bioanalyzer; both Agilent Technologies, Santa Clara, USA) as 
well as the genome-wide expression profiling was provided by the genomic services of 
IMGM laboratories. As an index for RNA quality, the RNA integrity number (RIN) was 
used which is derived from the electrophoretic profile. The RIN scale ranges from 1 to 
10. A RIN of 10 denotes an excellent RNA quality, while a RIN value of 1 indicates 
massive degradation. For RIN calculation, the algorithm does not rely on the 28S/18S-
rRNA ratio alone, but takes the entire electrophoretic profile into account. GeneChip® 
Human Gene 1.0 ST arrays (Affymetrix, Santa Clara, USA) were used in combination 
with a random-priming and one-color based hybridization protocol. Briefly, 200 ng of 
total RNA was spiked with polyadenylated transcripts using the Gene Chip® Poly-A 
Control kit (Affymetrix). Subsequently, RNA was reverse transcribed into cDNA and 
then converted into cRNA by in vitro transcription. The generated cRNA was 
transcribed into anti-strand and strand cDNA during a second cycle transcription. The 
strand cDNA was purified using the Ambion WT Expression kit (Life Technologies, 
Carlsbad, USA). The WT Terminal Labeling and Control kit (Affymetrix) were used to 
fragment the single stranded cDNA and label it with biotin. The labeled and fragmented 
sense-strand cDNA was spiked with cDNA hybridization controls (GeneChip 
Hybridization Control kit; Affymetrix), hybridized at 45°C for 17 h on separate 
GeneChip® Human Gene 1.0 ST arrays and stained in two binding cycles using anti-
biotin antibodies and streptavidin, R-phycoerythrin conjugates. For washing and 
preserving, the GeneChip® 3000 Fluidics Station in combination with the GeneChip® 
Command Console and the Fluidics Control software v3.2.0.1515 (all Affymetrix) were 
used. Fluorescent signal intensities were detected with the GeneChip® 3000 scanner 
and AGCC Scan Control software v3.2.3.1515 (both Affymetrix). An automatic grid was 
arranged and raw data (*.DAT files) were processed to generate image and intensity 
files (*.CEL, *.JPG) by the AGCC software. 
Transcriptome microarray analysis. Analysis of raw data, obtained from IMGM 
laboratories, was performed in collaboration with the laboratory of Cinthia Farina (San 
Raffaele Scientific Institute, Milan, Italy). The Affymetrix GeneChip® Human 
Gene 1.0 ST array comprised 33297 probes. Data were normalized and 26839 probes 
passed filtering criteria (p-value ≤ 0.05 in 25 % of the samples). No outliers were 
present based on principal component analysis and unsupervised hierarchical 
clustering. Differential gene expression was performed using the oneChannelGUI 
package160 implemented in the R-Bioconductor platform (FHCRC, Seattle, USA). The 
LIMMA172 algorithm, which implements the empirical Bayes method, as well as the 
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Benjamini&Hochberg method were used to adjust the p-value. Genes, fulfilling the 
following criteria, were considered to be regulated: p ≤ 0.05, fold-change ≥ |1.4| and 
expression level ≥ 100 in one group.  
3.2.6 Secretome analysis 
The secretome analysis was performed in collaboration with the laboratory of 
Stefan Lichtenthaler (DZNE, Munich). Protein enrichment using the recently developed 
SPECS method99 and mass spectrometry measurements were performed by Peer-
Hendrik Kuhn (DZNE, Munich), as briefly summarized in the following paragraphs. 
Astrocyte stimulation and azido sugar labeling. Primary human astrocytes were 
grown and stimulated with FGF1 as described (3.2.3) with the following alterations: 
30 ml Panserin 401 medium per T175 cm3 cell culture flask was supplemented with 
10 ng/ml FGF1 and 5 U/ml heparin as well as 1 mmol/l of tetraacetyl-N-azidoacetyl-
mannosamine (ManNAz) obtained as a 50 µmol/l stock solution in ethanol (DZNE, 
Munich). Cells were grown in the presence of FGF1, heparin and ManNAz for 48 h at 
37°C, 10 % CO2. The conditioned supernatant was filtered (0.22 µm; Millipore, Billerica, 
USA) and further processed by Peer-Hendrik Kuhn. 
Secretome protein enrichment with click sugars (SPECS). The development and 
procedure of the SPECS method was described in detail before99. Briefly, free ManNAz 
present in the cell culture supernatant, was removed by centrifugal concentration 
(30 kDa cutoff, 4600 rpm, 4°C) using Vivaspin20® columns (Satorius, Goettingen, 
Germany) and H2O as concentrate diluent. The azide-labeled glycoproteins were 
biotinylated by addition of 100 nmol/l DBCO-PEG12-biotin (Click Chemistry Tools, 
Scottsdale, USA) in H2O and were incubated over night at 4°C. Free DBCO-PEG12-
Biotin was removed by centrifugal concentration as described for ManNAz. For 
denaturation, PBS with 2 mmol/l TCEP (Carl Roth) and 2 % SDS (v/v) (Bio-Rad) were 
added and the samples were loaded on a 10 ml Poly-Prep® chromatography column 
(Bio-Rad) equipped with streptavidin beads. Beads were washed with 1 % SDS (v/v) in 
PBS and boiled with 3 mmol/l biotin in urea sample buffer. Biotinylated glycoproteins 
were separated on a 10 % SDS gel. Bands, except of the BSA band (66.5 kDa), were 
cut and trypsin-digested169. 
Mass spectrometry and data analysis. Mass spectrometry analysis was performed 
on an Easy-nLC nanoflow HPLC system 1000 connected to an LTQ-Velos Orbitrap 
(both ThermoFisher). Peptides were separated by reverse phase chromatography (75-
min gradient, 5 % to 40 % acetonitrile, 250 nl/min flow rate). The measurement method 
consisted of an initial FTMS scan recorded in profile mode with 30 000 m/z resolution, 
a mass range from 300 to 2000 m/z and a target value of 1 000 000. Subsequently, 
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collision-induced dissociation fragmentation was performed for the 20 most intense 
ions with an isolation width of 2 Da in the ion trap. A target value of 10 000, enabled 
charge state screening, a monoisotopic precursor selection, 35 % normalized collision 
energy, an activation time of 10 ms, wide band activation and a dynamic exclusion list 
with 30 s exclusion time were applied. Three biological replicates were analyzed using 
the MaxQuant suite software version 1 (MPI of Biochemistry, Martinsried, Germany) 
with a UniProt database for Homo sapiens. 
Proteins displaying a significant change in expression in all experiments were 
categorized using a gene ontology enrichment tool31 (The Gene Ontology Consortium, 
http://amigo.geneontology.org/cgi-bin/amigo/term_enrichment, accessed in October, 
2013) 
3.2.7 Immunohistochemistry 
Tissue sectioning. Formalin fixed, paraffin embedded (FFPE) 4 µm sections of 
human control- and MS-brain as well as human adenoids (table 14) were cut at the 
laboratory of Tanja Kuhlmann (WWU Münster, Germany) within the scope of the SFB-
TR128.  
All images were acquired on either Leica LMD7000 or Leica DMI6000 microscopes 
(Leica Microsystems, Wetzlar, Germany) and processed using ImageJ software (NIH). 
Deparaffinization. FFPE sections were deparaffinized by performing the following 
washes: Two times 10 min XEM-200 (Xylol substitute; Vogel, Giessen, Germany), 
10 min 50 % XEM-200 (v/v) in ethanol, 5 min 100 % ethanol, 5 min 95 % ethanol, 5 min 
70 % ethanol, 5 min 50 % ethanol, final wash with H2O. 
Antigen retrieval. Heat induced epitope retrieval (HIER) was performed using a 
conventional steamer (Gastroback, Hollenstedt, Germany). Sections were boiled in 
pre-heated (95°C to 100°C) Tris-EDTA buffer (table 15) for 30 min, cooled to room 
temperature and subjected either to chromogenic- or fluorescence-staining. 
3.3'-Diaminobenzidine (DAB) staining. Following deparaffinization and HIER, the 
sections were rinsed for 5 min in 0.05 % Triton-X in PBS, followed by a PBS wash 
(5 min) and finally blocked with 10 % FCS and 1 % BSA in PBS for 1 h at room 
temperature. The primary antibodies were either incubated in 1 % BSA in PBS for 2 h 
at room temperature or overnight at 4°C. Sections were rinsed with PBS (three times 
5 min), incubated with 0.3 % H2O2 in PBS for 15 min at room temperature followed by a 
wash with PBS (5 min). Secondary biotin-conjugated antibodies in 1 % BSA in PBS 
were applied for 30 min at room temperature and the PBS wash was repeated (three 
times 5 min). Streptavidin-conjugated peroxidase was incubated for 30 min at room 
temperature, followed by a final PBS wash (three times 5 min). DAB chromogen was 
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diluted 1:50 in DAB buffer (both DAKO) and incubated until DAB precipitate appeared. 
Reaction was stopped by rinsing slides with H2O. If required, sections were incubated 
for 2 seconds in haematoxylin solution (Merck) and dehydrated by the following 
washes: 1 min 70 % ethanol, 1 min 95 % ethanol, 1 min 100 % ethanol, 1 min XEM-
200. Sections were mounted with Eukitt® mounting medium (Sigma-Aldrich). 
Luxol fast blue (LFB) staining. FFPE tissue sections were deparaffinized, hydrated 
to 95 % ethanol and incubated in LFB solution (table 16) over night at 60°C. Sections 
were rinsed in 95 % ethanol and subsequently in H2O. Sections were destained by 
incubation in 0.05 % aqueous lithium carbonate solution (Sigma-Aldrich) for 5 seconds 
and a subsequent 10 seconds wash in 70 % ethanol (destaining was repeated as 
required). Sections were rinsed in H2O, dehydrated and mounted with Eukitt® 
mounting medium.  
Fluorescence staining. Following deparaffinization and HIER the sections were 
rinsed for 5 min in 0.05 % Triton-X in PBS, washed in PBS (5 min) and blocked with 
10 % FCS and 1 % BSA in PBS for 1 h at room temperature. The primary antibodies 
were incubated as described for the DAB staining. Subsequently, fluorescent dye 
coupled antibodies with 1 µg/ml DAPI (Carl Roth) were applied for 30 min at room 
temperature. Sections were washed with PBS (three times 5 min) and mounted with 
Fluoromount G (SouthernBiotech). 
Tyramide signal amplification (TSA™). For fluorescence staining of FGF1, 
additional signal amplification was needed. Therefore, the TSA Plus Biotin kit 
(PerkinElmer, Waltham, USA) was used according to manufacturer instructions. Briefly, 
sections were deparaffinized, HIER was performed as described, sections were 
incubated with 0.3 % H2O2 for 15 min at room temperature and blocked with TSA 
blocking reagent (PerkinElmer). FGF1 antibody was incubated for 1 h, sections were 
washed with PBS (three times 5 min) and a secondary biotinylated antibody was 
applied for 1 h at room temperature. Sections were washed with PBS (three times 
5 min) and incubated with streptavidin-peroxidase for 30 min at room temperature. 
Following a PBS wash (three times 5 min), the signal was amplified by incubation with 
TSA reagent for 1 min. Sections were washed with PBS (three times 5 min) and the 
fluorescent dye-streptavidin construct was applied for 30 min at room temperature. 
Sections were washed (three times 5 min) and mounted with Fluoromount G. 
3.2.8 Lymphocyte isolation from human tonsils 
Human tonsils. Fresh human palatine tonsils (from tonsillectomies or tonsillotomies) 
were obtained from PD Dr. Klaus Stelter (Klinik und Poliklinik für Hals-Nasen-
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Ohrenheilkunde, Klinikum LMU, Germany) and processed immediately after the 
surgery. 
Lymphocyte isolation. After surgery, tonsils were transferred to ice-cold PBS 
supplemented with 1 % penicillin-streptomycin. Tissue was minced and single cell 
suspension was obtained by dissociating tissue through a 40 µm cell strainer (BD). 
Cells were centrifuged (300 g, 6 min, 4°C) and resuspended in ice-cold PBS. Cells 
were counted using a Neubauer hemocytometer. A maximum of 108 cells were purified 
from a total of 2x108 cells using magnetic anti-CD19 beads or anti-CD3 beads (Miltenyi, 
Bergisch Gladbach, Germany) for B cell depletion and T cell separation, according to 
manufacturer instructions. 
3.2.9 Enzyme-linked immunosorbent assay 
ELISA. For a complete list of ELISA kits used in this study see table 3. 96-well flat 
bottom MaxiSorp® plates (Nunc, Langenselbold, Germany) were used if pre-coated 
plates were not provided with the kit. Coating, incubation of cell supernatant and 
detection was performed according to manufacturer instructions. If substrate was not 
supplied with the kit, 3.3',5.5'-Tetramethylbenzidine (TMB) solution (Sigma-Aldrich) was 
used and color reaction was stopped by adding one volume of 1 mol/l H2SO4. 
Absorption was measured with a Wallac Victor2 1420 multilabel counter (PerkinElmer) 
at 450 nm and 540 nm, respectively. 
MMP9 activity assay. To measure active MMP9 (naturally occurring) or total active 
MMP9 (following activation with APMA), an ELISA-based MMP9 activity assay 
(QuickZyme) was used according to manufacturer instruction. Absorption was 
measured with a Wallac Victor2 1420 multilabel counter (PerkinElmer) at 405 nm after 
1 h and 4 h incubation, respectively. 
3.2.10 Flow cytometry 
Flow cytometry staining and data analysis. Cells were transferred into 96-well V-
bottom plates (Nunc), centrifuged at 280 g for 5 min at 4°C and washed once with 
200 µl flow cytometry buffer (table 17). Cell pellet was resuspended in 50 µl/well flow 
cytometry buffer containing directly labeled antibodies (table 1) and incubated for 
20 min at 4°C in the dark. Cells were washed three times and resuspended in 200 µl 
flow cytometry buffer. Fluorescence was measured using a FACSverse™ flow 





4.1 IN VITRO MYELINATING CULTURE 
4.1.1 Generation of in vitro myelinating cultures 
The method for the generation of in vitro myelinating cultures was originally 
developed for cells obtained from embryonic mouse spinal cords196 and modified for 
cells isolated from embryonic rat spinal cords in the laboratory of Susan Barnett58. The 
aim was to establish this method in our laboratory as a stable, reproducible and easy to 
quantify in vitro system, which could be used for determining effects of external stimuli 
on neurons and glial cells. Having established the in vitro myelinating culture system, it 
was used to determine effects of FGF1 on myelination and neuronal growth in an 
independent study in our laboratory (Mohan et al., in preparation). 
The changes in cell growth and morphology during the maturation of the in vitro 
myelinating cultures were followed using ICC. Antibodies detecting either neurofilament 
in axons (SMI-310) or MOG (Z2), a myelin protein which is specifically expressed on 
the outermost layer of the myelin sheath as well as in oligodendrocytes, were applied.  
A timeline indicating preparation and growth of the myelinating cultures (based on 
previously published data196 and results of the present study) is given in figure 8, A. To 
generate the astrocyte monolayer, cells were grown for 14 days in vitro (DIV). After 
seeding of the spinal cord cells, 28 DIV were needed to obtain fully myelinated 
cultures. After seeding, neuronal processes formed within two weeks in vitro, 
accompanied by the proliferation of OPCs in the presence of insulin in the cell culture 
medium196. During this time only few oligodendrocytes with short processes 
(figure 8, B; 10 DIV, inset) could be observed. Withdrawal of insulin supported the 
differentiation of oligodendrocytes, the formation of processes and the wrapping of 
axons (figure 8, B; 63x 28 DIV). An increase in myelination was especially detected 
between 15 and 24 DIV (figure 8, A and B). Myelination reached a maximum between 
24 and 28 DIV and cultures were used for experiments during this period. At later time 
points, cell death of astrocytes comprising the feeder layer was frequently observed 
and caused the subsequent death of neurons and oligodendrocytes 
(figure 8, B; 28 DIV). Therefore, the in vitro myelinating culture was not used for 
experiments at time points later than 28 DIV. 
Results 31 
 
Figure 8: Generation of in vitro myelinating cultures 
DIV: days in vitro; MC: in vitro myelinating cultures  
(A) Timeline: Generation of in vitro myelinating cultures. Neurosphere-derived astrocytes were generated 
14 days prior to the seeding of spinal cord cells. After having formed a confluent monolayer, the rat spinal 
cord cells were seeded on top of the astrocyte monolayer (0 DIV). Between 0 and 15 DIV neuronal 
processes and axons formed a dense mesh. This was followed by a phase of extensive myelination. 
Between 15 and 24 DIV myelination increased and peaked. Between 24 and 28 DIV, in vitro myelinating 
cultures were used for experiments. (B) Representative images of different time points after seeding of 
spinal cord cells. Neurons and axonal processes were visualized using a neurofilament-specific antibody 
(SMI-310, red). Oligodendrocytes and myelin were stained with a MOG-specific antibody (Z2, green). 
Nuclei were stained with DAPI (blue). From 10 to 12 DIV reticulated axonal processes could be observed. 
Only few immature oligodendrocytes (inset in 10 DIV) were detected. The number of oligodendrocytes 
increased over time (12 DIV). Insulin deprivation from the cell culture medium at 12 DIV resulted in 
maturation of oligodendrocytes and increased myelination of axonal processes (14 to 28 DIV). An 
enhanced cell death was observed at time points later than 28 DIV. Oligodendrocyte processes 
ensheathing axons could be observed at higher magnification (63x 28 DIV; arrowheads). Scale bars 
represent 50 µm (10x magnification) and 10 µm (63x magnification), respectively. 
4.1.2 Quantification of axonal density and myelination 
For the simple applicability of in vitro myelinating cultures, it is crucial to develop a 
rapid and easy to use method for the quantification of changes in myelination and 
axonal density. MetaMorph software was used to establish an automated quantification 
method in which 16-bit grayscale images, acquired with a Zeiss AxioVert200M 
microscope, were transformed into binary pictures. The binary pictures were corrected 
according to the shape factor and area of the objects. Subsequently, pixel values of the 
binary pictures could be used to calculate axonal density and myelination of the in vitro 
myelinating cultures (figure 9, A). 
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The in vitro myelinating cultures should be used as a bioassay to identify effects of 
external stimuli such as FGF1. To test, whether the quantification method allowed the 
detection of differences in axonal density and myelination caused by external stimuli, a 
previously established experiment was performed58. Cultures were treated with 
antibodies and complement to evaluate complement dependent degradation of axons 
and myelin. Besides appropriate isotype controls, antibodies targeting MOG (Z2 and 8-
18C5) as well as pan-neurofascin (A12/18.1) were used. MOG is localized at the 
outermost myelin sheath, whereas, the pan-neurofascin antibody detects isoforms 155 
and 186 present on oligodendrocytes and neurons. For visualization, antibodies 
detecting neurofilament (SMI-310) and MOG (Z2) were used (figure 9, B). 
The result of the quantification of one representative experiment is shown in figure 
9, C. The axonal density in medium treated control cultures was 37 ± 4.5 % with a 
myelination of 11.4 ± 1.5 % (figure 9, C; column 1). The treatment of myelinating 
cultures with the MOG-specific antibodies Z2 and 8-18C5 plus complement resulted in 
a complete degradation of myelin (figure 9, C, column 6 and 7). A representative image 
of Z2-mediated complement dependent degradation of myelin is shown in 
figure 9, B (63x Z2). Treatment with the pan-neurofascin antibody A12/18.1 depleted 
axons as well as myelin (figure 9, C; column 8). No reduction of myelin and axons was 
seen for complement without antibody and for the isotype controls (figure 9, C; 
column 2, 4 and 5). Z2 and heat-inactivated complement induced a slight 
demyelination (figure 9, C, column 3). The increase in axonal density seen in IgG1 
treated samples (figure 9, C, column 4) resulted most likely from an above average cell 
density and was not reproducible in subsequent experiments (not shown). 
Taken together, an in vitro myelinating culture system was established and a quick 
and easy to use method to assess changes in myelination as well as axonal density 
was developed. Reliability of the quantification method and the possibility of 
manipulating the system by application of external stimuli, were proven by antibody-
mediated complement dependent demyelination and axonal loss.  
The impact of FGF1 on in vitro myelinating cultures was tested in an independent 
study performed in our laboratory (Mohan et al, in preparation). 
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Figure 9: Quantification of antibody-mediated complement dependent effects on in vitro 
myelinating cultures 
RC wo ab: rabbit complement without antibody; HI/RC: heat-inactivated rabbit complement 
(A) Scheme for the quantification of axonal density and myelination. (B and C) In vitro myelinating cultures 
were treated with antibodies targeting neurofascin (A12/18.1) or MOG (Z2 and 8-18C5) plus complement. 
Additionally, control cultures were treated with: Medium (control), isotype controls plus complement (IgG1, 
IgG2a), Z2 plus heat-inactivated complement (Z2 HI/RC). (B) Representative images of antibody-mediated 
complement dependent effects on in vitro myelinating cultures. Neurons and axonal processes were 
stained with a neurofilament-specific antibody (red). Oligodendrocytes and myelin were stained with a 
MOG-specific antibody (green). In 63x magnification nuclei are visualized with DAPI (blue). Degradation of 
myelin can be observed (arrowheads). Scale bars represent 50 µm (10x magnification) and 10 µm 
(63x magnification). (C) Quantification of antibody-mediated complement dependent effects. Treatment 
with Z2 and 8-18C5 abolished myelin. Axons as well as myelin were completely depleted by treatment with 
A12/18.1 and complement. The result represents the mean of 10 images acquired from 3 replicates in one 
representative experiment. Error bars show SEM. 
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4.2 FGF1-MEDIATED EFFECTS IN HUMAN ASTROCYTES 
The second part of the present study can be considered as a follow up study of 
work which was previously performed in our laboratory (Mohan et al., in preparation). In 
the work of Mohan et al., a transcript profiling of different macro-dissected MS lesions 
was performed and FGF1 was found to be upregulated in remyelinated areas, 
suggesting a role of FGF1 in the regulation of myelination. The in vitro myelinating 
cultures, established as described before, were used to decipher the effects of FGF1 
on the regulation of myelination in vitro. FGF1 turned out to contribute to enhanced 
myelination (Mohan et al., in preparation). Based on this finding, the present work 
aimed at the identification of additional functions of FGF1 considering FGF-expressing 
astrocytes as target cells. 
4.2.1 Characterization of primary human astrocytes as a target of FGF1 
stimulation 
4.2.1.a RNA level of FGFRs in primary human astrocytes 
Primary human astrocytes were used as cell culture system to elucidate potential 
effects of FGF1. RT-qPCR was used to determine the RNA levels of FGFR1–FGFR4. 
The highest transcript level was detected for FGFR1. The FGFR4 level was 
approximately 7-fold lower compared to FGFR1. FGFR2 and FGFR3 were barely 
detectable (figure 10). No difference in the FGFR RNA levels could be detected for 
cells kept in serum-free medium (for FGF1 stimulation) or DMEM supplemented with 
10 % FCS (for routine cell culture; not shown). 
4.2.1.b HMOX1 level as an indicator for FGF1 responsiveness 
Heparin is well known to stabilize the interaction of various FGFs with their 
receptors72, 220, to induce oligomerization178 and to increase the stimulation efficiency168. 
Therefore, FGF1 together with heparin was applied to stimulate primary human 
astrocytes. The level of HMOX1 RNA was used as a positive control to establish 
optimal stimulation conditions as HMOX1 has previously been shown to be upregulated 
following FGF1 stimulation of astrocytes211. 5 U/ml heparin were incubated with either 
10 ng/ml or 50 ng/ml FGF1 for 8 h and 24 h, respectively. Heparin alone did not result 
in an increase of HMOX1 RNA compared to serum-free medium treated control cells 
(figure 11). In astrocytes, treated additionally with either 10 ng/ml or 50 ng/ml FGF1, 
the HMOX1 level was approximately 3.5-fold increased (figure 11). Although, 
stimulation with 10 ng/ml and 50 ng/ml FGF1 resulted in an elevated HMOX1 level, no 
further induction could be seen at the higher concentration. Therefore, in subsequent 




Figure 10: RNA level of FGFRs in primary human astrocytes 
Relative RNA levels of FGFR1 – FGFR4 in primary human astrocytes (% PPIA, housekeeping gene). 
Highest level was detected for FGFR1. Lower RNA levels were detected for FGFR4. RNA of FGFR2 and 
FGFR3 was barely detectable. Results represent the mean of three independent experiments; error bars 
show SEM. 
Taken together, of all FGFRs tested, FGFR1 exhibited the highest RNA level. Using 
the HMOX1 RNA level as positive control, 10 ng/ml FGF1 and 5 U/ml heparin were 
determined to be suitable for stimulating astrocytes. Heparin without FGF1 did not 
impact the HMOX1 level. 
 
 
Figure 11: HMOX1 level as an indicator for FGF1 responsiveness 
ns: not significant; p≤0.05 (*); p≤0.01 (**); p≤0.001 (***); p≤0.0001 (****) 
Stimulation of primary human astrocytes with heparin and FGF1. 5 U/ml heparin were incubated with 
either 10 ng/ml or 50 ng/ml FGF1 for 8 h and 24 h, respectively. Heparin alone did not increase the 
HMOX1 RNA level compared to astrocytes in serum-free medium. In astrocytes, additionally treated with 
either 10 or 50 ng/ml FGF1, HMOX1 levels were approximately 3.5-fold increased. Results represent the 
mean of n=4 (8 h, 10 ng/ml and 50 ng/ml FGF1), n=5 (heparin and 24 h 10 ng/ml FGF1) and n=6 (24 h 
50 ng/ml FGF1) independent experiments. T-test was used to calculate the significance of fold-changes; 
error bars show SEM. 
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4.2.2 Transcriptome microarray analysis 
Having determined suitable stimulation conditions and a proper control gene, the 
effects of FGF1 stimulation on primary human astrocytes were investigated using an 
Affymetrix GeneChip® Human Gene 1.0 ST array. The microarray screening service 
was provided by IMGM laboratories and the data was analyzed in collaboration with the 
laboratory of Cinthia Farina. The results of the Affymetrix GeneChip® Human Gene 
1.0 ST array, as obtained from the IMGM laboratories, are shown in 9.1. 
4.2.2.a Transcriptome microarray data analysis 
For analyzing differentially expressed genes (DEGs) significantly altered after FGF1 
stimulation, the RNA levels of medium-treated and FGF1-stimulated samples were 
compared. After normalization and filtering, the data were analyzed by principal 
component analysis and hierarchical sample clustering methods. No outliers were 
identified (hierarchical tree diagram in figure 12, A). DEGs were further analyzed as 
described in 3.2.5. A total of 272 DEGs after 8 h and 895 DEGs after 24 h of FGF1 
stimulation was detected (figure 12, B and C). Approximately 82 % (225 DEGs) of the 
genes regulated after 8 h were regulated in the same direction after 24 h. None of the 
identified genes was regulated in opposite directions at two different time points. After 
8 h the majority of DEGs (approximately 95 %) displayed fold-changes between 1.4- to 
3.0-fold and 0.7- to 0.3-fold, respectively (figure 12, C). A similar distribution was 
obtained after 24 h. However, the number of DEGs which were more than 4.0-fold and 
less than 0.25-fold regulated increased from 1 to 8 (DEGs upregulated) and from 0 to 2 
(DEGs downregulated), respectively (figure 12, C). 
In summary, by comparing heparin-treated with FGF1-stimulated human astrocytes 
at 8 h and 24 h, a total of 272 (8 h) and 859 (24 h) DEGs was identified. An intersection 
of 225 DEGs was expressed after 8 h and 24 h in equal directions. 
4.2.2.b Genes regulated in astrocytes upon FGF1 treatment  
The interpretation of a list of DEGs is facilitated if the genes exhibit similarities, e.g., 
in their functional annotation. A commonly used method, to handle large sets of data 
such as obtained from a transcriptome microarray analysis, is to perform an enrichment 
analysis to identify significantly represented pathways or gene ontology terms. 
Therefore, an enrichment analysis for FGF1-mediated pathways, processes, metabolic 
networks and for gene ontology terms was performed. This analysis pointed to an 




To get a further impression of FGF1-mediated effects in human astrocytes, the 
focus was set on genes which were found to be upregulated at 8 h and 24 h 
(115 DEGs, for a complete list see 9.2). Within this subset, genes with known functions 
in MS pathology were further analyzed. 8 DEGs with implications in MS were identified 
(figure 13, A and 9.2). These genes code for proteins which could be grouped into the 
following categories: (1) proteins, known to be elevated in response to acute 
inflammation (PTX3, IL8, HMOX1, PTHLH), (2) proteins with proinflammatory and 
immune modulatory roles (IL8, KCNN4, SPHK1), (3) proteins, impacting lymphocyte 
migration or the constitution of the ECM (NT5E, IL8) and (4) proteins with an 
established protective function in MS by the support of remyelination (LIF, IL8, PTX3). 
Four of them have already been identified to be elevated in serum and CSF of MS 
patients and/or EAE models (PTX3, IL8, SPHK1 and LIF). Changes in the RNA levels 
of these genes at 8 h and 24 h as determined by the transcriptome microarray analysis 
are shown in figure 13, A and C. 
In summary, among the 115 DEGs which were elevated in response to FGF1 
stimulation of human astrocytes after 8 h and 24 h, 8 DEGs with established functions 
in MS were identified and selected for further validations. 
 
 
Figure 12: Transcriptome microarray analysis of FGF1-stimulated human astrocytes 
(A) Hierarchical tree diagram. Applying the hierarchical tree clustering method, the samples could be 
divided in two distinct groups representing untreated control samples and FGF1-stimulated samples. No 
outliers were identified. (B) Total number of genes which were found to be regulated at 8 h, 24 h and at 
both time points (8 h / 24 h). None of the genes was found to be regulated in opposite directions at two 
different time points. Approximately 82 % of the DEGs found to be regulated after 8 h were also detected 
after 24 h. (C) Fold-changes in the RNA level of DEGs at 8 h and 24 h. Approximately 95 % of all DEGs 
displayed changes in the RNA level between 1.4- to 3.0-fold and 0.7- to 0.3-fold, respectively. The total 
number of DEGs altered more than 4.0-fold and less than 0.25-fold increased at 24 h. In “8 h / 24 h” the 
fold-changes detected at 24 h are depicted. 
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4.2.2.c Validation of the transcriptome microarray analysis 
The results, obtained from the transcriptome microarray analysis were validated by 
determining the RNA levels of DEGs with implications in MS (figure 13, A). Using RT-
qPCR, an induction could be demonstrated for all of them at 8 h and 24 h 
(figure 13, B). Due to variations between independent replicates, not all tested genes 
appeared to be significantly altered at both time points (figure 13, B). Direct comparison 
of fold-changes in the RNA levels detected in the transcriptome- and the RT-qPCR-
approach revealed a strong correlation of results. Fold-changes in RNA levels 
determined by RT-qPCR were equal to or higher than the fold-changes obtained from 
the transcriptome approach (figure 13, C). 
Taken together, results obtained from the transcriptome microarray analysis could 
be validated for genes with known implications in MS by RT-qPCR. By comparing the 
fold-changes in RNA levels detected in the different approaches, a strong correlation 
was found.  
4.2.3 Secretome analysis 
4.2.3.a Identification of glycosylated and secreted proteins 
Besides the transcriptome microarray analysis a secretome analysis was performed 
to unravel FGF1-mediated effects in human astrocytes which might not have become 
apparent by screening the RNA levels. The secretome analysis comprised the labeling 
of secreted and glycosylated proteins with the recently established SPECS method99 
and the subsequent analysis of these proteins using mass spectrometry. 303 proteins 
were identified to be regulated in the cell culture supernatant of FGF1-treated human 
astrocytes (figure 14) of which 72 proteins were significantly changed (for a complete 
list of significantly induced proteins see 9.3). 33 out of 72 proteins were increased and 
39 out of 72 proteins were decreased. In average, proteins were altered ± 3.32-fold 
compared to heparin-treated control samples. 19 out of 72 proteins exceeded this 
average (>│3│-fold). Of the 19 proteins 11 were detected to be up- and 8 were down-




Figure 13: Validation of transcriptome microarray data 
p≤0.05 (*); p≤0.01 (**) 
(A) Elevated DEGs identified in the transcriptome microarray analysis after 8 h and 24 h FGF1 stimulation. 
DEGs chosen for validation using RT-qPCR are highlighted on the right. The fold-changes in RNA levels 
detected at 8 h and 24 h are stated. (B) Validation of transcriptome results using RT-qPCR. Elevation of 
the RNA level was proven for all tested DEGs. Results represent the mean of three independent samples. 
T-test was used to calculate the significance of fold-changes, error bars show SEM. (C) Comparison of the 
fold-changes in RNA levels detected in the transcriptome and the RT-qPCR approach. The fold-changes 




Figure 14: Glycosylated proteins in supernatant of FGF1-treated astrocytes 
Proteins identified in the cell culture supernatant of FGF1-treated human astrocytes. Horizontal dashed 
line determines the threshold for p<0.05. Vertical dashed lines represent the average protein induction 
(│3│-fold). Black circles and dots: proteins identified in two out of three independent experiments (n≠3). 
Green circles: upregulation < 3-fold. Red circles: downregulation < 3-fold. Green dots: upregulation > 3-
fold. Red dots: downregulation > 3-fold. Labels of proteins regulated >│3│-fold are included. 
4.2.3.a Grouping of induced proteins based on gene ontology 
The FGF1-regulated proteins were grouped using a gene ontology enrichment 
tool31 (3.2.6). Twelve specific gene ontology terms were identified which comprised at 
least five of the proteins detected in the secretome approach (figure 15, A). Proteins 
belonging to the identified gene ontology terms are listed in table 18.  
Three out of twelve identified gene ontology groups were directly linked to ECM 
degradation and ECM adhesion. Those were: “collagen catabolic process”, “cell-matrix 
adhesion” and “ECM disassembly”. Furthermore, FGF1 signaling led to an induction of 
proteins involved in the biological process of “cell migration” and “chemotaxis”. Proteins 
belonging to these groups largely overlapped with those involved in “axon guidance” 
(compare table 18). In addition, FGF1 treatment led to an induction of proteins 
participating in “wound healing” which also comprised proteins involved in “blood 
coagulation” and “platelet activation” (compare table 18). Finally, proteins participating 
in “blood vessel development”, “enzyme linked receptor protein signaling pathways” 
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and in the “response to growth factor stimuli” were detected to be mediated by FGF1 
treatment of human astrocytes (all summarized in figure 15, A). 
The focus was set on proteins which stood out because of their strong FGF1-
dependent up- or downregulation (alteration >│3│-fold; compare figure 14). This group 
comprised 19 proteins of which 11 were up- and 8 were downregulated. Interestingly, 
≥75 % of the proteins which were >│3│-fold regulated belonged to the two gene 
ontology groups “collagen degradation” and “ECM disassembly” (figure 15, B). Within 
other gene ontology groups, proteins >│3│-fold regulated represented 25 % to 47 % of 
the proteins (figure 15, B). 
This suggests that FGF1 stimulation of human astrocytes mainly has an impact on 
the degradation and the disassembly of the ECM. Proteins upregulated >3-fold in these 
groups were: MMP1, MMP9 and TIMP1 (a modulator of MMPs). Proteins, 
downregulated >3-fold in these groups were: COL1A1, COL1A2, COL4A2 and 
COL5A2 (compare figure 14).  
Taken together, proteins detected in the secretome analysis could be assigned to 
twelve specific gene ontology groups using a gene ontology enrichment tool. The focus 
was set on proteins which were induced above average in response to FGF1 treatment 
(>│3│-fold). They were found to be disproportionately represented in the gene ontology 
groups “collagen catabolic process” and “ECM disassembly”. ECM degrading enzymes 
such as MMP1 and MMP9, as well as the MMP regulator TIMP1 were strongly 
enhanced, whereas, essential constituents of the ECM (COL1A1, COL1A2, COL4A2, 
and COL5A2) were diminished.  
 
 
Figure 15: Classification of proteins according to their gene ontology 
(A) Gene ontology grouping of induced proteins. (B) Percentage of proteins which were induced above 
average (≥│3│-fold) belonging to the different gene ontology groups. The biological functions “collagen 
catabolic processes” and “ECM disassembly” peaked out because ≥75 % of the proteins in these groups 
were more than ≥│3│-fold induced in response to FGF1 treatment of human astrocytes. 
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4.2.3.b RNA levels of proteins identified in the secretome approach 
To validate the secretome results, the RNA levels of strongly induced proteins 
belonging to the ontology groups “collagen catabolic process” and “ECM disassembly” 
were determined by RT-qPCR. Furthermore, as none of the collagens was detected to 
be regulated in the transcriptome approach, the question should be answered whether 
the reduction of collagens could result from increased degradation instead of a 
decrease in RNA levels. Therefore, the RNA levels of MMP1, MMP9, TIMP1 and of the 
collagens COL1A1, COL1A2, COL4A2 and COL5A2 were determined. 
 
Table 18: Grouping of induced proteins based on gene ontology 
Gene ontology grouping Genes/proteins 
Collagen catabolic process COL1A1, COL6A1, COL5A2, MMP9, CTSB, MMP1, COL1A2, COL4A2 
Cell-matrix adhesion CTGF, ITGA3, UCC1, SERPINE1, THBS1, ITGB1, CSF1, NID1, CDH13, CD44 
ECM disassembly COL1A1, COL6A1, COL5A2, MMP9, CTSB, MMP1, TIMP1, COL1A2, COL4A2 
Cell migration TGFB2, CTGF, COL1A1, ITGA3, MET, SLC3A2, CSPG4, SERPINE1, IGFBP3, MMP9, 
LRP1, THBS1, ITGB1, CSF1, AXL, MMP1, PTK7, TIMP1, CDH13, COL1A2, NRP1, 
MYH9 
Chemotaxis TGFB2, COL6A1, MET, BOC, COL5A2, SERPINE1, SEMA7A, THBS1, ITGB1, NEO1, 
ALCAM, GPC1, CDH13, COL4A2, NRP1, MYH9 
Response to growth factor 
stimulus 
TGFB2, CTGF, COL1A1, UBC, SERPINE1, NDST1, THBS1, ITGB1, GPC1, COL1A2, 
COL4A2, NRP1, CD44 
Enzyme linked receptor 
protein signaling pathway 
TGFB2, CTGF, UBC, CSPG4, SERPINE1, IGFBP3, NDST1, LRP1, PDGFC, THBS1, 
AXL, FSTL3, GPC1, CDH13, COL1A2, NRP1 
Blood vessel development TGFB2, CTGF, COL1A1, CSPG4, SERPINE1, ANGPTL4, LRP1, THBS1, ITGB1, 
CDH13, COL1A2, COL4A2, NRP1, LOX, MYH9 
Wound healing TGFB2, ALDOA, COL1A1, ITGA3, SLC3A2, SERPINE1, ACTN4, DCN, THBS1, ITGB1, 
AXL, MMP1, PTK7, TIMP1, COL1A2, LOX, CD44 
Blood coagulation TGFB2, ALDOA, COL1A1, ITGA3, SLC3A2, SERPINE1, ACTN4, THBS1, ITGB1, AXL, 
MMP1, TIMP1, COL1A2 
Platelet activation TGFB2, ALDOA, COL1A1, SERPINE1, ACTN4, THBS1, AXL, TIMP1, COL1A2 
Axon guidance TGFB2, COL6A1, MET, BOC, COL5A2, SEMA7A, ITGB1, NEO1, ALCAM, GPC1, 
COL4A2, NRP1, MYH9 
 
The relative RNA levels of the four collagens were determined in untreated human 
astrocytes. The highest RNA level was found for COL1A1, followed by COL1A2 and 
COL4A2. Minor levels of COL5A2 were detected (figure 16, A). The changes in RNA 
levels after FGF1 stimulation were detected at three different time points which 
represented the stimulation conditions used in the transcriptome microarray analysis 
(8 h, 24 h) and the secretome analysis (48 h), respectively. For COL1A1, COL1A2 and 
COL4A2 a stepwise decrease in RNA upon increasing stimulation periods could be 
demonstrated (figure 16, B). The RNA level of COL4A2 was detected to be significantly 
altered only after 48 h of FGF1 stimulation, whereas, COL1A1 and COL1A2 displayed 
significant alterations after 24 h. The RNA level of COL5A2 was significantly reduced 
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after 24 h but did not further decrease upon longer FGF1 incubation (figure 16, B). 
None of the collagens was significantly altered after 8 h.  
RNA levels of MMP1, MMP9 and TIMP1 were also determined. Upon FGF1 
treatment RNA levels of all three genes increased at 8 h, 24 h and 48 h (figure 16, C). 
However, due to strong alterations in fold-changes detected in independent 
experiments, significance could not be proven at all time points (figure 16, C).  
Taken together, data obtained from the secretome analysis could be validated by 
determining the RNA levels of MMP1, MMP9 and TIMP1 as well as of COL1A1, 
COL1A2, COL4A2 and COL5A2. Furthermore, the decrease in collagen protein could 




Figure 16: RNA levels of proteins identified in the secretome approach 
ns: not significant; p≤0.05 (*); p≤0.01 (**); p≤0.001 (***) 
(A) Relative RNA levels of COL1A1, COL1A2, COL4A2 and COL5A2 in untreated human astrocytes 
(% PPIA, housekeeping gene). Results represent the mean of three independent experiments; error bars 
show SEM. (B) Changes in the RNA level of collagens after 8 h, 24 h and 48 h FGF1 treatment of human 
astrocytes. COL1A1, COL1A2 and COL4A2 RNA levels decreased over time. COL4A2 was significantly 
altered only after 48 h. COL5A2 was significantly downregulated after 24 h and did not further decrease at 
48 h. None of the collagens was significantly altered at 8 h. (C) Changes in the RNA level of MMP1, MMP9 
and TIMP1 after 8 h, 24 h and 48 h of FGF1 treatment in human astrocytes. RNA levels were found to be 
upregulated at all three time points. Results represent the mean of three independent experiments. T-test 
was used to calculate the significance of fold-changes, error bars show SEM. 
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4.2.3.c MMP9 protein concentration and enzymatic activity 
To answer the question whether the reduction of collagens can be partly attributed 
to the increased degradation by an elevated expression of MMPs, an MMP9 activity 
assay was performed. MMP9 is known to degrade collagen IV and collagen V171 and 
does play an important regulatory role in the penetration of lymphocytes into the CNS3. 
To determine the protein concentration of MMP9 in the cell culture supernatant and 
to distinguish between active MMP9 and its inactive pro-enzyme, a MMP9 activity 
assay was applied after 48 h FGF1 treatment. In this ELISA-based activity assay the 
cleavage of pro-MMP9 into active MMP9 is catalyzed by AMPA. The concentration of 
active MMP9 is subsequently determined by degradation of a MMP9 substrate. Without 
AMPA, no MMP9 activity was detected in the cell culture supernatant of FGF1-treated 
astrocytes and heparin-treated controls (figure 17). AMPA-dependent cleavage of pro-
MMP9 resulted in a significant increase of active MMP9 in FGF1-treated samples. An 
average concentration of 1300 pg/ml active MMP9 was measured. It was concluded 
that MMP9 protein, elevated in human astrocytes in response to FGF1, was present as 
zymogen in the cell culture supernatant. A minor level of MMP9 protein could also be 
detected in heparin-treated control samples (figure 17). 
 
 
Figure 17: MMP9 protein concentration based on enzymatic activity 
p≤0.05 (*); Hep: heparin-treated astrocytes; FGF1: FGF1-stimulated astrocytes 
Protein concentration of active MMP9 in the cell culture supernatant of human astrocytes stimulated with 
FGF1 for 48 h. Inactive pro-MMP9 was activated by AMPA-dependent cleavage. MMP9 concentration was 
determined by means of its substrate degrading activity. Without AMPA, MMP9 activity was neither 
detected in heparin-treated control samples nor in FGF1-treated samples. AMPA-dependent cleavage of 
MMP9 significantly increased MMP9 activity in the FGF1-treated samples. Results represent the mean of 
three independent experiments. T-test was used and concentrations of active MMP9 were log10-
transformed to converge to normal distribution, error bars show SEM. 
Taken together, MMP9 present in the cell culture supernatant of FGF1-treated 
astrocytes was detected to be inactive by using an MMP9 activity assay. AMPA-
dependent activation of MMP9 demonstrated a significantly increased concentration of 
active MMP9 in FGF1-treated astrocytes compared with control samples. 
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4.2.4 Comparison of secretome and transcriptome results 
Proteins identified after 48 h in the cell culture supernatant of FGF1-treated primary 
human astrocytes, were compared with results obtained from the transcriptome 
microarray analysis after 8 h and 24 h, respectively. Of 72 proteins significantly 
changed in the secretome approach, 15 were also found to be regulated on the RNA 
level in the transcriptome microarray analysis. 14/15 proteins were regulated in equal 
directions on the RNA level. The regulation of RNA and protein levels of PTK7 was 
found to be the only exception (table 19; figure 18). Inactive tyrosine-protein kinase 7 
which is encoded by the PTK7 gene, found to be 2.13-fold elevated in the cell culture 
supernatant, whereas, the corresponding RNA level was 1.41-fold decreased at 24 h 
(table 19, figure 18). However, as changes on the protein and RNA level were rather 
low, the relevance of this discrepancy remains elusive.  
 
Table 19: Proteins detected to be altered in the secretome as well as in the 
transcriptome approach 













CD44 antigen P16070 CD44 26.99 - 1.53 
Semaphorin-7A O75326 SEMA7A 10.98 3.13 4.17 
Interstitial collagenase P03956 MMP1 10.84 2.23 8.74 
CUB domain-containing protein 1 Q9H5V8 CDCP1 6.90 - 2.00 
Angiopoietin-related protein 4 Q9BY76 ANGPTL4 5.94 4.71 4.37 
Metalloproteinase inhibitor 1 P01033 TIMP1 5.30 - 1.51 
Neuropilin-1 O14786 NRP1 2.18 - 1.64 
Inactive tyrosine-protein kinase 7 Q13308 PTK7 2.13 - -1.41 
Follistatin-related protein 3 O95633 FSTL3 -1.51 - -1.40 
Calsyntenin-2 Q9H4D0 CLSTN2 -1.69 - -1.50 
Serine protease 23 O95084 PRSS23 -1.80 - -1.56 
Heparan sulfate N-deacetylase/N-sulfotransferase 1 P52848 NDST1 -1.87 - -1.41 
Stanniocalcin-2 O76061 STC2 -2.82 - -1.81 
Protein KIAA1199 Q8WUJ3 KIAA1199 -3.69 -1.45 -4.01 
Transforming growth factor beta-2 P61812 TGFB2 -5.19 - -1.93 
ACCN: Accession number; FC: fold-change; Sec: Secretome; Trans: Transcriptome; Protein/RNA levels 
altered in opposite directions are double underlined. 
15 out of 72 proteins identified in the secretome approach were detected to be regulated in the 
transcriptome microarray analysis. 
For 11/15 proteins, changes in RNA expression could be detected after 24 h. 
4/15 proteins exhibited changes in RNA expression already at 8 h. Those were: 
Semaphorin 7A, interstitial collagenase, angiopoietin-related protein 4 and protein 
KIAA1199 (table 19, figure 18).  
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Most of the identified proteins and corresponding RNAs were altered in the same 
direction (qualitative correlation). In contrast, the fold-changes of RNA and protein 
induction did not correlate (no quantitative correlation). That means, a high induction on 
the RNA level did not always lead to a high induction on the protein level and vice 
versa (figure 18). This becomes obvious considering the fold-changes in protein and 
RNA levels of CD44 (figure 18) which is a proteoglycan implicated in several adhesion 
events. CD44 peaked out in the secretome approach as it was highly induced (26.99–
fold), whereas, the CD44 RNA level was barely elevated in the transcriptome 
microarray analysis (1.53–fold at 24 h). The reason why CD44, a membrane bound 
protein, is found to be elevated in the secretome approach is unknown. A possible 
explanation, however, could be the enhanced cleavage of cell surface bound CD44. 
The quantitative differences between protein and RNA levels could result from 
different incubation times used in the transcriptome (8 h, 24 h) and the secretome 
approach (48 h). Therefore, it was determined whether fold-changes of protein and 
RNA levels quantitatively correlated at 8 h and 24 h, respectively. Protein 
concentrations of three different proteins were determined in the cell culture 
supernatant at 8 h and 24 h. Those were: (1) LIF, which displayed an increase of the 
RNA level at 8 h (1.92-fold) and 24 h (1.66-fold) in the transcriptome approach. 
(2) IL11, which was slightly elevated at 8 h (1.45-fold) and was not detected at 24 h in 
the transcriptome approach. (3) MMP9, which was not detected in the transcriptome 
approach (8 h, 24 h) but in the secretome approach (48 h). 
 
 
Figure 18: Comparison of FGF1-induced changes in RNA and protein levels 
RNA and protein levels were found to be altered in equal directions for 14/15 proteins identified in the 
secretome and the transcriptome approach (qualitative correlation). PTK7 constituted the only exception. 
No correlation was found for the fold-changes of protein and RNA levels (no quantitative correlation). 
Using ELISA, we found protein levels of LIF, IL11 and MMP9 to be significantly 
elevated at 8 h and to be further increased at 24 h (figure 19, A). Direct comparison of 
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the fold-changes detected for the RNA level (transcriptome approach) and the protein 
level (ELISA) revealed no quantitative correlation at 8 h and 24 h (figure 19, B). 
Therefore, the difference between changes in RNA and protein levels is not exclusively 
caused by the different incubation times used in the secretome and the transcriptome 
approach. 
Taken together, of 72 proteins which were identified to be altered in the secretome 
approach, 15 were also found to be regulated in the transcriptome approach. For 
14/15 proteins, the protein and RNA levels were altered in equal directions (qualitative 
correlation). However, no correlation of the fold-changes of RNA and protein levels was 
found (no quantitative correlation). To exclude, that this was due to different incubation 
times used in the transcriptome (8 h, 24 h) and the secretome approach (48 h), the 
protein concentrations of LIF, IL11 and MMP9 were determined at 8 h and 24 h. No 




Figure 19: Protein and mRNA levels of LIF, IL11 and MMP9 at 8 h and 24 h 
p≤0.05 (*); p≤0.01 (**); p≤0.001 (***); Hep: heparin-treated astrocytes; FGF1: FGF1-stimulated astrocytes 
(A) Protein concentration of LIF, IL11 and MMP9 in the cell culture supernatant of astrocytes after 8 h and 
24 h of FGF1 stimulation. FGF1 treatment significantly elevated protein concentrations at 8 h and 24 h. LIF 
and IL11: Results represent the mean of three independent samples. MMP9: Results represent the mean 
of three independent experiments. Concentrations of MMP9 were log10-transformed to converge to normal 
distribution. T-test was used; error bars show SEM. (B) Comparison of FGF1-induced fold-changes of 
RNA and protein levels. No correlation was found for the fold-changes of protein and RNA levels at 8 h 
and 24 h. 
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4.3 FGF1-POSITIVE CELLS IN MS LESIONS 
4.3.1 Characterization of FGF1-positive cells in control brain and MS 
lesions 
FGF1 is known to exhibit widespread functions in the developing as well as in the 
adult brain and is expressed by various cell types in the CNS, predominantly by 
neurons but also by glial cells153. In the transcriptome and secretome analysis, FGF1 
was found to mediate the induction of a multitude of genes and proteins in human 
astrocytes, pointing to diverse functions of FGF1 in mediation of inflammation, tissue 
repair mechanisms as well as the disintegration of extracellular matrix. To evaluate 
functions of FGF1 in MS lesion environment, IHC was used to characterize different 
FGF1-positive cell types in human control brain and MS lesions. FGF1 in gray and 
white matter of control brain, NAWM of MS brain, remyelinated lesions, demyelinated 
lesions and in active lesions was analyzed. 
To determine FGF1-positive cells contributing to high levels of FGF1 in normal 
brain, post-mortem FFPE brain specimens from healthy controls were stained. In white 
matter, FGF1 staining was detected in glial cells, which according to the morphology, 
were oligodendroglia (figure 20, A). FGF1-positive oligodendroglia were also detected 
in NAWM surrounding MS lesions (figure 20, B). However, not all the oligodendroglia 
detected in white matter of control brain and in NAWM of MS lesions were FGF1-
positive. Often, FGF1-positive oligodendroglia were found to be focally accumulated, 
whereas, other parts of the control white matter and the NAWM were free from FGF1 
staining. Besides oligodendroglia, neurons of the cortical gray matter were found to be 
FGF1-positive in control brain (figure 20, C) and in gray matter parts of MS lesions (not 
shown). As for oligodendroglia, FGF1 staining was found only in a subset of neurons. 
No staining was detected using an IgG1 isotype control (not shown). 
 
 
Figure 20: FGF1-positive oligodendroglia and neurons 
FGF1 (DAB) staining of post-mortem FFPE brain specimens obtained from healthy controls and MS 
patients. (A) FGF1-positive cells with oligodendroglial morphology in control brain white matter. (B) FGF1-
positive cells with oligodendroglial morphology in the NAWM of a MS lesion. (C) FGF1-positive neurons in 
gray matter of control brain. Scale bars represent 100 µm. 
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FGF1 appeared to be regulated in MS lesions as previously detected in our 
laboratory (Mohan et al., in preparation). Particularly, it was upregulated in 
remyelinated lesions compared to demyelinated lesions and NAWM. Seven post-
mortem MS tissue specimens containing remyelinated lesions were stained (listed in 
table 14). The overview of a representative lesion (Nbb 03-074 # 3) is shown in 
figure 21. In the remyelinated as well as demyelinated areas, cells with ramified 
processes were FGF1-positive (figure 21, A, a and b). However, density of FGF1-
positive cells was largely reduced in demyelinated compared to remyelinated parts of 
the lesion (figure 21, A, a and b). As expected, double staining of FGF1 with the 
astrocyte marker GFAP revealed these cells to be hypertrophic astrocytes forming a 
compact glial scar (figure 21, B, a-c). Nevertheless, not all reactive astrocytes exhibited 
FGF1 staining. Some astrocytes, with a rather mild hypertrophic phenotype localized in 
the NAWM were found to be GFAP-positive but FGF1-negative (figure 21, C, a-c).  
In addition, active and chronic active MS lesions were investigated for FGF1-
positive cells. A LFB and HE stain of a representative chronic active lesion as well as 
the corresponding staining of macrophages and microglia is shown in figure 
22, A and B. FGF1-positive macrophages and microglia were identified by double 
staining of FGF1 with the pan-macrophage marker Iba-1 (figure 22, C). Comparable to 
the observations made for neurons, oligodendroglia and astrocytes, not all the 
microglia and macrophages present in the lesion were FGF1-positive. FGF1-negative 
Iba1-positive cells could be observed (not shown). The distribution of FGF1-positive 
and negative cells was independent of the lesion type (active or chronic active). 
Analyzing active MS lesions with a high number of perivascular infiltrates, a 
prominent FGF1 staining was detected in some lymphocytes residing in these 
perivascular cuffs (figure 23). Double staining of FGF1 with T cells (CD3) and B cells 
(CD20) markers, revealed FGF1 expression in both cell types (figure 23, B and C). 
Compared to T cells the number of B cells in active MS lesions is rather small. 
Nevertheless, in some of the observed lesions a substantial number of B cells were 
present within the perivascular cuffs (figure 23, C). 
Taken together, various FGF1-positive cell types in control brain as well as in 
different types of MS lesions were detected. Subsets of oligodendroglia in white matter 
of control brain and NAWM in MS lesions were shown to express FGF1. Additionally, 
subsets of neurons in gray matter of control brain were FGF1-positive. Hypertrophic 
astrocytes were found to be FGF1-positive in re- as well as in demyelinated lesions. In 
(chronic) active lesions, Iba-1/FGF1-double positive macrophages and microglia were 
observed. Furthermore, double staining with CD3 and CD20 revealed FGF1-positive 




Figure 21: FGF1-positive astrocytes in re- and demyelinated MS lesions 
(A) LFB staining of a representative post-mortem MS tissue specimen containing gray matter (GM), 
normal appearing white matter (NAWM), remyelinated (RE) as well as demyelinated (DE) areas. Images 
(a) and (b) were acquired in box-highlighted areas. (a) DAB staining of FGF1 in remyelinated lesions. Cells 
forming a dense mesh of ramified processes were FGF1-positive. (b) DAB staining of FGF1 in 
demyelinated lesions. Cells with ramified processes were FGF1-positive. Cell count was decreased 
compared to remyelinated lesions. Scale bars represent 25 µm. (B) Fluorescence staining of GFAP and 
FGF1. (a) GFAP and DAPI (b) FGF1 and DAPI (c) merged and magnified image of the boxes highlighted 
in (a) and (b). Arrowhead indicates a double positive astrocyte. (C) Hypertrophic astrocytes in NAWM 
surrounding MS lesions. (a) GFAP and DAPI (b) FGF1 and DAPI (c) merged and magnified image of the 
boxes highlighted in (a) and (b). Open arrowhead indicates a GFAP-positive, FGF1-negative cell. Scale 




Figure 22: FGF1-positive macrophages and microglia 
(A) LFB and HE stain of a representative chronic active lesion. (B) KiM1P-positive macrophages and 
microglia at the rim of the lesion. Image was acquired in the box-highlighted area in (A). (C) FGF1 and Iba-
1 double staining of macrophages and microglia at the lesion rim. (a) Iba-1 and DAPI (b) FGF1 and DAPI 
(c) merged image. Arrowheads indicate a double positive cell. Scale bars represent 25 µm. 
4.3.2 FGF1 in adenoids and in CD3-positive T cells from human tonsils 
So far, only few studies reported about FGF1 expression in lymphocytes. 
Therefore, it was investigated whether FGF1-positive lymphocytes could also be 
detected in lymphatic tissues. Using FFPE sections of human adenoids, FGF1-positive 
cells were found to be mainly located in germinal centers (figure 24, A, a). Germinal 
centers represent the site of B cell proliferation and differentiation. Therefore, they are 
rich in B cells and low in T cells (figure 24, A, b). Double staining with CD3 
(figure 24, B), CD20 (figure 24, C) as well as the macrophage marker CD68 
(figure 24, D) revealed that FGF1 staining colocalized with CD3 and no double staining 
was detected for CD20 or CD68 (figure 24, B-D). 
The results obtained from FGF1 staining in human adenoids were confirmed by 
determining the FGF1 RNA level in human tonsils. Lymphocytes were isolated from 
human tonsils immediately after surgery. CD3 and CD19-positive lymphocytes were 
purified using magnetic beads and purity of the isolated fractions was checked by flow 
cytometry. CD3-positive T cells could be isolated with a purity of 95 %. 83 % of the 
cells were CD4-positive and 16 % of the cells revealed to be CD8-positive (not shown). 
For CD19-positive B cells a purity of 96 % was obtained (not shown). RNA was isolated 
from purified B and T cells and FGF1 levels were determined using RT-qPCR. The 
relative RNA level of FGF1 in lymphocytes was low and did not exceed 6x10-3 % PPIA 
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(figure 25). The low level of FGF1 matched the IHC findings in which of a small 
subpopulation of CD3-positive cells was found to be FGF1 positive. Relative FGF1 
levels varied between tonsils from different patients. In accordance with IHC results, 
T cells contributed the major part of the detected FGF1 level in human tonsils 
(figure 25).  
 
 
Figure 23: FGF1-positive T cells and B cells in perivascular cuffs of active lesions 
(A) Mouse IgG1 isotype control for FGF1 (a) CD3 and DAPI (b) mouse IgG1 isotype control and DAPI 
(c) merged and magnified image of the boxes highlighted in (a) and (b). (B) FGF1-positive T cells. (a) CD3 
and DAPI (b) FGF1 and DAPI (c) merged and magnified image of the boxes highlighted in (a) and (b). 
(C) FGF1-positive B cells. (a) CD20 and DAPI (b) FGF1 and DAPI (c) merged and magnified image of the 




Figure 24: FGF1-positive T cells in the germinal center of human adenoids 
(A) FGF1 and CD3 staining of human adenoids. (a) FGF1-positive cells were mainly detected in germinal 
centers (GC) (b) merged image of FGF1 and CD3 staining in GC. Nuclei were stained with DAPI (blue). 
Scale bars represent 100 µm. (B) FGF1-positive T cells. (a) CD3 and DAPI (b) FGF1 and DAPI (c) merged 
image of (a) and (b). Boxes highlight CD3/FGF1-double positive T cells. (C) FGF1-negative B cells 
(a) CD20 and DAPI (b) FGF1 and DAPI (c) merged image of (a) and (b). No colocalization of FGF1 and 
CD20 was detected. (D) FGF1-negative macrophages (a) CD68 and DAPI (b) FGF1 and DAPI (c) merged 




Figure 25: Relative FGF1 levels in lymphocytes purified from tonsils 
Relative FGF1 RNA levels in B and T cells isolated from human tonsils (% PPIA, housekeeping gene). 
Approximately 95 % purity was obtained for T and B cells fractions determined by flow cytometry (not 
shown).The FGF1 RNA level in T cells exceeded the FGF1 level in B cells. Results from two independent 
experiments are shown. Error bars show SD of 6 technical replicates. 
Taken together, by double staining of human adenoid tissue with FGF1 and 
antibodies specific for T cells, B cells and macrophages, FGF1-positive T cells were 
found to be mainly localized within germinal centers. This finding could be 
substantiated by isolation of B cells and T cells from fresh human tonsils and the 
subsequent quantification of the relative FGF1 level using RT-qPCR. The FGF1 RNA 
level in T cells exceeded the FGF1 level detected in B cells. 
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5 DISCUSSION 
5.1 IN VITRO MYELINATING CULTURE 
In vitro myelinating cultures were originally derived from mouse spinal cords196 and 
later modified for cells isolated from rats58. These in vitro myelinating cultures were 
established in our laboratory. Furthermore, using MetaMorph software a rapid and easy 
to use quantification method was developed to determine changes in myelination as 
well as axonal density induced by external stimuli. Reliability of the quantification 
method was checked by reproducing antibody-mediated complement dependent 
demyelination or axonal loss, as described before58. 
In accordance with the work of Elliot et al.58, the effect seen for different CNS-
specific antibodies was highly selective. The results obtained for the anti-MOG 
antibodies (Z2 and 8-18C5) as well as for isotype controls (IgG1, IgG2a) were 
comparable to published results58. A minor difference was detected in effects mediated 
by the neurofascin antibody A12/18.1. In the present study, A12/18.1 induced 100 % 
loss of both, myelin and axons. Elliot et al.58, in contrast, found a complete abolishment 
of myelin but only a reduction in axonal density of around 40 %. Furthermore, in the 
present study Z2 plus heat-inactivated complement induced a slight demyelination, in 
contrast, in58 no demyelination was seen. A possible explanation for these differences 
is the usage of complement from a different source (rabbit complement instead of fresh 
rat serum) and in a higher final concentration (2.5 % instead of 1 % complement in 
medium). In our system, total loss of axons and/or myelin could already be detected 
after 90 min, whereas, incubation times of 3-4 h were reported before58. Nonetheless, 
toxicity of the complement itself can be excluded as complement alone did not affect 
myelinating cultures. Demyelination in samples treated with Z2 plus heat-inactivated 
complement might be caused by incomplete inactivation. Therefore, differences 
between the present work and previously published results58 can most likely be traced 
back to variations in the conduction of the experiments and do not account for invalidity 
of the quantification approach. It is important to mention, however, that quality and 
reproducibility of screenings strongly depend on the quality of the cultures. Variations in 
axonal density and myelination might be observed between independent replicates. To 
obtain reliable and reproducible results, an adequate number of replicates and 
independent experiments for each condition must be used. 
In summary, by introducing this culture system in combination with a quantification 
method, a valuable tool to study effects of externally applied factors was obtained. This 
was demonstrated by antibody-mediated complement dependent cell damage. To shed 
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light on potential functions of FGF1 on different CNS cells, myelinating cultures were 
stimulated with FGF1. Thereby, FGF1 was found to promote myelination (Mohan et al., 
in preparation). 
5.2 FGF1-MEDIATED EFFECTS IN HUMAN ASTROCYTES 
In a study previously performed in our laboratory (Mohan et al., in preparation) 
transcript profiling of macro-dissected tissue of different types of MS lesions was 
conducted. FGF1 was one the factors identified to be differentially expressed in distinct 
lesion types. In particular, it was found to be upregulated in re- compared to 
demyelinated lesions as well as compared to control white matter. This raised the 
question of the role of FGF1, known to be abundantly expressed in adult brain153, in the 
context of MS lesion formation and/or repair. 
As FGFRs are expressed on a variety of cells in the CNS, including 
oligodendrocytes, neurons and astrocytes, FGF1 can have a multitude of regulatory 
functions. Astrocytes are important mediators in MS lesion formation and can exert 
beneficial but also detrimental functions216. To unravel the FGF1-mediated effects in 
astrocytes, the focus of the second part of this study was set on FGF1-induced 
changes in RNA and protein levels in astrocytes and how these could impact MS 
pathology. 
5.2.1 Characterization of primary human astrocytes as a target of FGF1 
stimulation 
Astrocytes are known to express different FGFRs on their surface and can be 
activated by FGF141. Using RT-qPCR the expression of FGFR1 - FGFR4 in primary 
human astrocytes was evaluated. The highest RNA level was detected for FGFR1. 
However, low levels of FGFR2, FGFR3 and FGFR4 could also be demonstrated. The 
presence of FGFR1 on human astrocytes is in accordance with studies of Balaci14 and 
Stachowiak179 who used northern blot analysis, immunoprecipitation and 
immunocytochemistry to demonstrate FGFR1 expression in fetal human astrocytes as 
well as in astrocytes derived from adult trauma patients. The decreased sensitivity of 
both techniques used in these studies compared to RT-qPCR might account for the 
absence of FGFR2 and FGFR314 and FGFR2 – FGFR4179, respectively. Supporting 
data comes also from studies with rodents in which expression of FGFR1 in rat-derived 
astrocytes18 as well as in brain from adult rats152 was shown. Interestingly, FGFR1 was 
described to be upregulated in astrocytes in response to brain injury152 and transient 
ischemia188. Nonetheless, there are also studies based on IHC which report the 
presence of FGFR242 and FGFR315 in adult rat brain. These studies, however, did not 
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consider expression of other FGFR subtypes. These previous findings strongly support 
the assumption that also in the adult brain astrocytes do express different types of 
FGFRs and findings gained from in vitro work with fetal human astrocytes can, with the 
usual limitations, be transferred to conditions in adult cells. 
HMOX1 was previously shown to be upregulated in rat astrocytes in response to 
FGF1 stimulation211. In the present study the HMOX1 RNA level was chosen as a 
positive control for the stimulation of human astrocytes with FGF1. A FGF1 
concentration of 10 ng/ml in presence of 5 U/ml heparin led to a 3.5-fold increase of 
HMOX1 RNA levels at 8 h and 24 h, respectively. Heparin without FGF1 did not have 
any impact on the HMOX1 level and a higher concentration of FGF1 (50 ng/ml) did not 
further enhance HMOX1 RNA levels. In the study of Vargas et al.211, the HMOX1 
elevation was most pronounced at 4 h, and decreased with increasing incubation 
times, resulting in non-significant elevation after 24 h. In contrast, in the present study, 
elevation of HMOX1 did not decrease at longer incubation and was still significant at 
24 h. The reason for this difference is unclear. However, one might speculate that the 
interaction of recombinant human FGF1, used in both the studies, is more stable with 
human FGFRs than with rat FGFRs. This might lead to prolonged binding and 
stimulation and therefore to prolong elevation of HMOX1 in human astrocytes. 
Regardless, as the HMOX1 RNA level was significantly elevated at the indicated time 
points, it served as a suitable control for FGF1 stimulation of primary human 
astrocytes.  
5.2.2 Transcriptome microarray analysis 
To discover FGF1-mediated functions in human astrocytes, a transcriptome 
microarray analysis was performed. Human astrocytes were incubated for either 8 h or 
24 h with FGF1 and differential gene expression was evaluated. A total of 272 (8 h) 
and 859 (24 h) DEGs were identified of which 115 were upregulated at 8 h as well as 
24 h. Within this subset of 115 DEGs the focus was set on those, with established 
functions in MS. Namely, PTX3, IL8, HMOX1, NT5E, EGR1, KCNN4, SPHK1 and LIF. 
FGF1-induced increase in the RNA levels was validated by RT-qPCR. An increased 
RNA level was detected for all selected genes at both time points. The congruent 
results obtained from the transcriptome microarray analysis and the RT-qPCR 
approach strongly argue for the validity of the array analysis. 
It is possible that FGF1, by increasing the RNA levels of these factors, might also 
influence functions known to be mediated by the genes/proteins in MS. In the 
subsequent chapter, potential MS relevant aspects of PTX3, IL8, HMOX1, NT5E, 
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EGR1, KCNN4, SPHK1 and LIF are briefly summarized. A survey is also given in 
table 20.  
Pentraxin 3 (PTX3). PTX3 is a prototypic long pentraxin which by binding to C1q 
can activate the complement cascade and might amplify inflammation and the innate 
immune response. It was shown to be induced during inflammation and by 
inflammatory cytokines10, 22, 141. In brain, PTX3 is not constitutively expressed. However, 
evidence was found for induction of PTX3 in glial cells and neurons upon 
intracerebroventricular injection of LPS or IL1β141. In EAE, PTX3 was elevated in 
response to inflammation2 which correlates with the recent finding of elevated PTX3 
plasma levels during the inflammatory response in MS and NMO212. Furthermore, 
PTX3 is known to bind specifically to FGF2 (not FGF1) and thereby inhibits its 
activity158. In EAE, FGF2 was shown to promote proliferation and to inhibit 
differentiation of OPCs125. Therefore, the FGF1-dependent elevation of PTX3 might 
directly influence inflammation on the one hand and modulate remyelination by 
promoting differentiation of oligodendrocytes on the other hand. 
Interleukin 8 (IL8). IL8 is an intensely studied CXC chemokine with known functions 
on degranulation of neutrophils and neutrophil transmigration167. It has also been 
described as chemo-attractant for monocytes, triggering their firm adhesion to 
endothelial cells68. It is expressed by a variety of cells in response to different 
inflammatory stimuli (for review see167) and is, therefore, often associated with 
inflammation. It acts via binding to two receptors, namely CXCR2 and CXCR1167. In 
astrocytes, IL8 production is upregulated in response to inflammatory stimuli such as 
TNFα and IL1β8. Furthermore, evidence was found for IL8-dependent production of 
MMPs in endothelial cells106 which could promote ECM degradation and support cell 
migration. CXCR1 and CXCR2 were additionally found in an oligodendrocyte precursor 
cell line132, in human oligodendrocytes in vitro and, importantly, upregulated on 
oligodendrocytes in MS lesions136. Their ligand IL8 was detected in astrocytes around 
active MS lesions136. Therefore, crosstalk between astrocytes and oligodendrocytes 
could be mediated by IL8 interaction with its receptors. This could be implicated in the 
recruitment or in proliferation of oligodendrocyte and thus in the regeneration of 
demyelinated lesions132. FGF1-mediated elevation of IL8 in astrocytes, therefore, could 
be pro-inflammatory but could also have a modulating function in remyelination. 
Heme oxygenase 1 (HMOX1). HMOX1 is responsible for the degradation of heme 
to biliverdin/bilirubin, free iron and carbon monoxide. In Alzheimer’s as well as in 
Parkinson’s disease it was found to be overexpressed in neurons and astrocytes164. In 
MS plaques, a disproportionately high number of HMOX1-expressing astrocytes was 
detected124. Evidence exists for a neuroprotective function of HMOX1 against different 
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toxic stimuli such as oxidative damage43, 62, 191. However, whereas the acute induction 
of HMOX1 is predominantly protective, persistent or repeated upregulation of the 
HMOX1 in astrocytes, oligodendroglia and possibly neurons may lead to cellular 
dysfunction in chronic degenerative and neuroinflammatory diseases. Thus, HMOX1 
could contribute to pathological conditions164, 180. In active MS lesions, HMOX1 might 
be upregulated as a secondary response to inflammatory stimuli such as TNFα and 
IL1β62, 124, 150. Thereafter, the increase of HMOX1 in astrocytes could raise iron deposits 
in the vicinity of MS plaques105, 124. In EAE, increased levels of HMOX1 were reported 
in oligodendrocytes105, 180. Furthermore, evidence was provided that acute HMOX1 
expression could confer cytoprotection against oxidative stress, whereas, long term 
induction exacerbated oxidative injury180. Therefore, FGF1-mediated elevation of 
HMOX1 can initially be protective. However, it may also be detrimental in chronic MS. 
5’ nucleotidase (CD73). CD73 is a cell surface enzyme expressed by various cell 
types including subsets of lymphocytes217, endothelial95 as well as epithelial cells184. In 
the CNS, CD73 is also expressed by astrocytes, oligodendrocytes and microglia227. In 
astrocytes its expression was shown to be regulated by inflammatory factors35. During 
inflammation, ATP is released from damaged cells and cleaved to AMP in the 
extracellular environment. CD73 mediates the catalytic cleavage of AMP into 
adenosine. Extracellular adenosine is known to have strong immunosuppressive 
effects, whereas extracellular ATP acts proinflammatory30. Thereby, effects mediated 
by ATP and adenosine regulate the immune response and prevent an uncontrolled 
inflammation and a damage of healthy tissue30. Adenosine can also be directly 
protective in the CNS by regulating neuronal survival156. Furthermore, on peripheral 
blood lymphocytes CD73 has been shown to act as a costimulatory molecule and 
controls adhesion to endothelial cells5. In a study using CD73-/- mice it was found that 
these mice were highly resistant to induction of EAE127. In EAE, CD73 was not only 
found to regulate the entry of lymphocytes into the CNS but also generated 
extracellular adenosine by its enzymatic activity127. Besides immunosuppressive 
functions that might be mediated by FGF1-dependent elevation of CD73 levels, CD73 
could; also via adenosine signaling, increase lymphocyte migration into the CNS. 
Early growth response 1 (EGR1). EGR1 is a zinc-finger transcription factor and 
functions as transcriptional regulator for differentiation and mitogenesis. Additionally, it 
is also known to induce expression of inflammatory factors in peripheral organs218 or in 
the CNS in response to ischemia205. Therefore, amongst transcription factors which are 
known to be involved in brain damage, it is considered to be proinflammatory222. 
Furthermore, it appeared to be significantly elevated in a microarray based screening 
of the gene expression profile of MS brain lesions130. FGF1, by elevating the EGR1 
60 Discussion 
RNA level, might be involved in the production of proinflammatory cytokines in 
astrocytes, thereby, modulating the immune response during neuroinflammation. 
Intermediate conductance Ca2+-activated K+-channel protein 4 (KCNN4). The 
KCNN4 gene codes for the voltage independent K+-channel KCa3.1 which opens in 
response to minor increases in intracellular calcium levels87. Strong evidence was 
found that KCa3.1 can regulate activation and proliferation of certain T-lymphocyte 
subsets70, 90. Comparably little is known about KCNN4/KCa3.1 expression in the CNS. 
However, there are studies showing in vitro KCa3.1 expression on microglia88 and in 
vivo upregulation in astrocytes after spinal cord injury29. Blocking of KCa3.1 resulted in 
an increased locomotor recovery and a reduced secondary damage as well as 
production of proinflammatory mediators such as TNFα, IL1β and iNOS29. Furthermore, 
blocking of KCa3.1 in EAE reduced clinical disability and also led to a reduction of 
proinflammatory chemokine/cytokine expression151. This suggests that KCNN4/KCa3.1 
is important for inflammatory cytotoxicity and the FGF1-mediated elevation of the 
KCNN4 RNA level in astrocytes might increase production of proinflammatory 
cytokines. 
Sphingosine kinase 1 (SPHK1). SPHK1 is a critical enzyme in the synthesis of 
sphingosin-1-phosphate (S1P) from ceramide. It catalyzes the final, ATP-dependent 
phosphorylation of sphingosine140. S1P is a lysophospholipid which has been 
implicated as a crucial regulator in a broad range of physiological conditions, e.g., 
angiogenesis, vascular permeability, wound healing, apoptosis, cardiovascular function 
and immunity177. These functions are mediated by binding of S1P to its receptors 
S1P1–S1P534, 135. Due to the clinical approval of fingolimod as oral therapy for MS, 
which targets S1PRs, the S1P/S1PRs pathway has also received increased attention in 
autoimmune diseases33. In the CNS, importance of S1P/S1PR signaling has been 
reported for several pathological conditions. This includes: Alzheimer’s disease190, 
ischemia92, stress85, pain45, but also multiple sclerosis100. In healthy spinal cords S1P 
was mainly detected in neurons93. However, an increased synthesis was detected by 
reactive astrocytes and microglia upon tissue injury11, 93. S1P was also found to be 
elevated in the CSF of MS patients100. Additionally, an enhanced expression of 
SPHK163 as well as its receptors S1P1 and S1P3208 was found on reactive astrocytes 
in tissue specimens of MS brain. Furthermore, fingolimod treatment of reactive primary 
human astrocytes led to a reduced expression of proinflammatory cytokines208, 
suggesting that this effect might contribute to the clinical outcomes of fingolimod 
treatment. An upregulation of the SPHK1 RNA level in astrocytes would therefore 
support a proinflammatory function of FGF1. 
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Leukemia inhibitory factor (LIF). LIF is a neurotrophic cytokine of the CNTF family 
which was not only shown to play a key role in neuronal but also in oligodendrocyte 
survival. It was found to support oligodendrocyte survival in vitro21, 118 and in vivo39, 89 
and also reduced clinical severity in EAE39. Furthermore, LIF was released from 
astrocytes in response to ATP81 and upon activation of TNFR264 and was shown to 
promote maturation of oligodendrocytes64 and myelination81. Therefore, LIF gathered a 
lot of attention for the treatment of neurodegenerative diseases and autoimmune 
demyelination (see148 for review). Besides its effects on neuronal and glial cells, it was 
found to interact with the immune system. Evidence was found for both pro- and anti-
inflammatory effects of LIF. Deploying LIF deficient mice, it was found that proliferation 
of thymocytes was impaired upon ConA stimulation61 and microglia/macrophage 
invasion was decelerated after spinal cord injury185. Furthermore, it was demonstrated 
to be an attractant for macrophages185, 197. On the other hand, endogenous and 
exogenous LIF was shown to reduce signs of inflammation in cutaneous inflammation 
induced by Freund’s adjuvant16, 226. Only few studies applied LIF-/- mice to investigate 
its role in CNS inflammation. However, in MOG-induced EAE LIF deficiency resulted in 
an attenuation of the disease in the late phase and the maintenance of the 
inflammatory infiltrates was altered107. This adds an additional aspect to LIF-mediated 
functions and suggests that it might orchestrate T cell and macrophage responses in 
EAE. Taken together, besides its protective role, LIF also seems to act as an 
immunomodulator. FGF1 stimulation of human astrocytes increased the LIF transcript 
level and the secretion of LIF in the cell culture supernatant (figure 19). Depending on 
the lesion type, present cells and cytokine levels, FGF1 could mediate different 
functions by enhancing the RNA level of LIF in astrocytes.  
In summary, by FGF1 treatment of human astrocytes and a transcriptome 
microarray analysis, a wide range of mediators which are implicated in MS lesion 
development were identified and validated. Known effects which are mediated by these 
FGF1-mediated factors could roughly be grouped into two categories: The regulation of 
myelination and the modulation of inflammation.  
FGF1 was found to promote myelination in the in vitro myelinating culture system 
established in the present study as well as remyelination in a slice culture model 
(collaboration with T. Kuhlmann, Mohan et al., in preparation). The mechanisms behind 
FGF1-promoted myelination are not yet clear. In this study three mediators were 
identified which might promote myelination and were induced in astrocytes in response 
to FGF1, namely, LIF, IL8 and PTX3. This suggests a contribution of these factors to 
FGF1 effects on myelination. 
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In addition to regulating myelination, data indicated that FGF1 modulates 
inflammation and might trigger the complex response of astrocytes to tissue damage. 
The astrocyte response to FGF1 mirrors multiple aspects of the response to 
proinflammatory stimuli such as TNFα and IL1β (table 20). This finding is in agreement 
with the work of Lee et al103, who demonstrated that FGF1 stimulation of cultured 
astrocytes and microglia enhanced LPS and/or IFNγ-mediated neurotoxicity by 
increasing the expression of proinflammatory cytokines (TNFα and INFβ).  
 
Table 20: FGF1-dependent regulation of genes with implications in MS 
Gene 
name 
Protein Protein function Implications in neuroinflammation / MS / EAE 
PTX3 Pentraxin 3, 
long 
- Innate resistance to 
pathogens 
- PTX3 is induced during the active phase of EAE2 
- PTX3 is elevated in serum of in MS and NMO 
patients212 
IL8 Interleukin 8 
(CXCL8) 
- Chemokine 
- Mediator of tissue damage in 
acute inflammation 
- Chemo-attractant for 
monocytes68 
- Increased levels in MS112 
- Produced by astrocytes upon TNFα and IL1β 
treatment8 
- Can stimulate MMP2 and MMP9 synthesis106 
- Found on astrocytes in active MS lesions136 
- Upregulation of CXCR1 and CXCR2 on 
oligodendrocytes in MS lesions136 
HMOX1 Heme 
oxygenase 1 
- Microsomal enzyme 
- Degradation of heme groups 
to yield biliverdin, iron, and 
carbon monoxide 
- HMOX1-positive astrocytes in MS spinal cord124 
- Pro-oxidant and inflammatory stimuli can induce 
HMOX1 in CNS glia62, 150 





- Plasma membrane protein 
- Hydrolyzation of AMP into 
adenosine 
- CD73 expression is required for lymphocyte entry into 
the CNS5, 127 
- CD73-/- mice were highly resistant to induction of 
EAE127 
EGR1 Early Growth 
Response 1 
- Transcriptional regulator - Enhanced expression in MS lesions130 








potassium channel activated 
by intracellular calcium 
- Blocking reduced production of proinflammatory 
mediators after spinal cord injury29 




- Phosphorylation of 
sphingosine to form 
sphingosine 1-phosphate 
(S1P) 
- Upregulated in astrocytes of MS patients63 
- Elevated S1P levels in CSF of MS patients100 




- Pleiotropic cytokine of the 
CNTF family 
- Neuroprotective170 
- Limits autoimmune demyelination and oligodendroglial 
loss39, 170 
- Promotes remyelination in vitro81 
- Elevated LIF levels in the CSF of MS patients115 
- Modulation of immune response107, 170 
DEGs upregulated after 8 h and 24 h in FGF1-treated human astrocytes with possible implications in MS. 
DEGs were identified by a transcriptome microarray analysis and changes in RNA expression were further 
validated by RT-qPCR (figure 13) and ELISA (LIF; figure 19). 
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It is self-evident that one can get only a limited insight in the actual FGF1-
dependent astrocyte-mediated functions by examining FGF1-induced differential gene 
expression. The multitude of effects which FGF1 triggers in other cell types of the MS 
lesion environment adds an additional dimension to the considerations of FGF1-
regulated processes in the context of MS pathology. Nevertheless, FGF1 led to a vast 
induction of genes with various functions in MS. Together with the previous finding of 
differential FGF1 expression in MS lesions (Mohan et al., in preparation) this supports 
the assumption of FGF1 being an important regulator in MS lesion development. 
5.2.3 Secretome analysis 
Besides the transcriptome microarray analysis, a secretome analysis was 
performed to unravel FGF1-mediated effects in human astrocytes which might not have 
become apparent by screening the RNA level. In total, 72 proteins were found to be 
significantly altered in response to FGF1 of which 33 were up- and 39 were 
downregulated. These 72 proteins detected in the secretome analysis could be 
assigned to 12 specific groups using gene ontology classification (figure 15). The focus 
was set on proteins which were induced above average in response to FGF1 treatment 
(>│3│-fold). They were found to be disproportionately represented in the two gene 
ontology groups “collagen catabolic process” and “ECM disassembly”. Within these 
groups ECM degrading metalloproteinases (MMP1, MMP9) and metalloproteinase 
regulators (TIMP1) were strongly induced, whereas, constituents of the ECM (COL1A1, 
COL1A2, COL4A2, COL5A2) were diminished. Results of the secretome analysis were 
validated by RT-qPCR. Using an activity assay, MMP9 was found to be present in the 
cell culture supernatant of astrocytes as zymogen.  
Induction of MMP1 and MMP9. In the present study it was found that MMP1 and 
MMP9 were strongly induced in astrocytes following FGF1 stimulation.  
Matrix metalloproteinases (MMPs) are endopeptidases, best known for their ability 
to cleave components of the ECM. They are expressed during embryonic development 
and in pathological situations in which tissue remodeling occurs. MMPs are 
synthesized as inactive zymogens containing a pro-peptide domain and are activated 
in the extracellular lumen. This activation can be catalyzed by other MMPs, the 
plasmin-plasminogen cascade, and a range of proteinases and nonproteolytic 
agents223 and is strictly regulated by chemokines and cytokines. 
MMP9 is known to degrade collagen IV and collagen V171, whereas collagen I can 
be degraded by MMP1171. MMP9 does play an important regulatory role in the 
penetration of lymphocytes into the CNS, which is under normal healthy conditions 
limited by the BBB3. 
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The BBB is formed by capillary endothelial cell, which are surrounded by the basal 
lamina, pericytes and astrocyte foot processes1. The microvasculature of the CNS has 
a specialized double basement membrane structure. In the CNS, endothelial cells of 
post-capillary venules are ensheathed by an underlying endothelial basement 
membrane. This endothelial basement membrane covers the pericytes. A second 
parenchymal basement membrane, synthesized by astrocytes is ensheathing the 
endothelial basement membrane60. 
During inflammation, infiltrating leukocytes first cross the endothelial cells and the 
endothelial basement membrane before they accumulate as so called “perivascular 
cuffs” in the perivascular space between endothelial and parenchymal basement 
membranes. It has been shown that the mechanisms by which leukocytes cross the 
endothelial- and the parenchymal basement membranes, differ. In EAE, peripheral 
macrophages seem to be associated with penetration of the endothelial basement 
membrane202, whereas, it was shown that MMP9 and MMP2 activity was essential for 
leukocytes to cross the parenchymal basement membrane3. Importantly, astrocytes 
were found to be anchored by dystroglycan to the parenchymal basement membrane, 
which can be cleaved by MMP9 and MMP23. Thereby, the stability of the basement 
membrane could be compromised. The expression of MMP9 by astrocytes was found 
to be elevated in response to oxidative stress192, thrombin44, TNFα12 or tissue 
plasminogen activator104 stimulation.  
Besides the role of MMPs in remodeling of the ECM during development and 
regeneration, also other aspects have been reported. MMPs are strictly regulated and 
can modulate the immune response. This can be achieved by cleavage of cytokines 
which inactivates67, 82, 165 or modulates206 their function or by the specific cleavage of 
ECM components213 resulting in fragments with altered functions. MMP9, e.g., was 
shown to inactivate CXCL12122 and to activate IL8206, CXCL6 and CXCL5207. MMP1 on 
the other hand was shown to cleave monocyte chemoattractant proteins which can act 
as antagonists for their cognate CC chemokine receptors123. It has also been shown 
that MMPs can impact glial scar formation as well as the scar composition54. MMP9, in 
particular, was demonstrated to support the formation of glial scars in injured spinal 
cord and, furthermore, facilitated astrocyte migration in vitro78. 
Therefore, FGF1-induced upregulation of MMP9 could directly impact the integrity 
of the BBB and impact leukocyte infiltration into the CNS. Additionally, FGF1-mediated 
upregulation of MMP1 and MMP9 could release or modify ECM-anchored cytokines or 
impact glial scar formation.  
Few studies report about the induction of MMPs in response to FGF1. However, 
FGF1-mediated upregulation of MMP1 in human lung fibroblast was described and 
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FGF1 was suggested to reduce lung fibrosis25. Comparable to results of the present 
study, FGF1 treatment was shown to increase MMP1 and to reduce collagen I. In 
contrast, no changes in TIMP1 expression were seen in fibroblasts25. Furthermore, 
FGF1-dependent induction of MMP9 was seen in breast cancer cells and was 
suggested to be involved in metastasis113.  
Induction of TIMP1. Besides MMP1 and MMP9, TIMP1 was found to be 
upregulated in response to FGF1.  
Following activation, MMP activity can be modulated by TIMPs32. An imbalance of 
TIMP and MMPs is implicated in different CNS diseases, including Parkinson’s 
disease110, brain tumors131 but also MS96. Because of its role in BBB maintenance, 
TIMP1 was shown to convey neuroprotection in the CNS. Amongst the family of 
TIMPs, TIMP1 is inducible and is known to be upregulated in reactive astrocytes by 
proinflammatory cytokines38. An increased expression has also been reported by 
astrocytes in EAE134. The increase of TIMP1 may serve to counterbalance the 
simultaneous rise in MMP9131 which supports the role of TIMP1 as an endogenous 
factor expressed to modulate MMP-dependent ECM remodeling during 
neuroinflammation9. However, also MMP-independent functions have been described 
for TIMP1 as it was shown to induce proliferation of astrocytes and OPC 
differentiation129. Therefore, the FGF1-dependent upregulation of TIMP1 could, on the 
one hand, counterbalance the simultaneous upregulation of MMP1 and MMP9, on the 
other hand, it could impact proliferation and differentiation of glia cells. 
Reduction of collagens. Whereas MMP1, MMP9 and TIMP1 were found to be 
induced by FGF1 in astrocytes, the protein level of different collagens was reduced. 
Those were: COL1A1 and COL1A2, which are major components of fibrillar type I 
collagen and the main component of the interstitial membrane. COL4A2 is part of 
type IV collagen, an important component of basement membranes175. Like collagen I, 
COL5A2 is a fibrillar collagen, however, with a low abundance and normally found in 
association with collagen I. 
The ECM in the CNS has a unique composition. Fibrous proteins such as 
collagens, laminins and fibronectin are present in low amounts, whereas, 
glycosaminoglycans such hyaluronan, chondroitin sulfate and heparan sulfate are more 
frequent133, 149, 210. The ECM does have a structural role but does also provide physical 
support for CNS cells, is involved in the regulation of homeostasis and can act as a 
growth factor reservoir149. Several studies have shown an alteration in the composition 
of the ECM during the course of MS, including the increased immunoreactivity for 
collagen IV around blood vessels209. 
66 Discussion 
In a study performed by Mohan et al.128, IHC was used to demonstrate that fibrillar 
collagens were strongly induced in MS lesions, whereas, minor levels of fibrillar 
collagens were detected in brain from healthy controls. In particular, collagen I, 
collagen III and collagen V formed a dense meshwork in the perivascular space of MS 
lesions128. Evidence was provided that perivascular fibrosis is a feature of chronic 
lesions as it was less pronounced in active compared to chronic active lesions128. 
Therefore, perivascular fibrosis might act as a physical barrier limiting the invasion of 
immune cells into the CNS. 
Therefore, an FGF1-dependent decrease in protein levels of fibrillar collagens, such 
as COL1A1, COL1A2 and COL5A2 as well as non-fibrillar collagens such as COL4A2, 
an important component of basement membranes, could have a direct impact on the 
invasion of immune cells during the course of MS. 
In summary, the upregulation of ECM degrading enzymes and the simultaneous 
downregulation of different components of fibrillar collagens and of collagen IV, 
strongly suggest that FGF1 signaling in astrocytes plays an important role in the 
remodeling of the ECM which is implicated in MS pathology. This could not only enable 
cell growth and migration but also might trigger the release of cytokines that are 
anchored in the ECM. Furthermore, cytokines could be processed and regulate the 
immune response. Additionally, due to the known role of MMP9 in the degradation of 
parenchymal basement membranes and the facilitation of leukocyte entry into the CNS, 
FGF1 signaling in astrocytes might directly enhance the permeability of the basement 
membrane. MMP9 and TIMP1 are both upregulated during the acute phase of injury or 
inflammatory processes in the CNS134, 192 and the expression is induced by 
proinflammatory cytokines12, 38. This supports the findings of the transcriptome 
microarray analysis that FGF1 might act as mediator in acute inflammation triggering 
the complex detrimental or protective response of astrocytes to tissue damage, as it is 
known for proinflammatory stimuli such as TNFα and IL1β. 
5.2.4 Comparison of secretome and transcriptome results 
In the present study, two independent approaches were used to unravel FGF1-
mediated effects in human astrocytes. In the transcriptome approach FGF1 was found 
to increase RNA levels of factors involved in modulation of myelination and 
inflammation, whereas, in the secretome analysis an effect of FGF1 on remodeling of 
the ECM was revealed. 
FGF1-induced proteins, identified in the secretome approach (n=72) were directly 
compared with differentially expressed genes (272 DEGs at 8 h and 859 DEGs at 24 h) 
detected in the transcriptome microarray analysis. Of 72 proteins which were identified 
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to be altered in the secretome approach, 15 were also found to be regulated in the 
transcriptome approach. For 14/15 proteins, the protein and RNA levels were altered in 
equal directions (qualitative correlation). However, no correlation of the fold-changes of 
RNA and protein levels was found (no quantitative correlation). To exclude, that this 
was due to different incubation times used in the transcriptome (8 h, 24 h) and the 
secretome approach (48 h), the protein concentrations of LIF, IL11 and MMP9 were 
determined at 8 h and 24 h. No correlation of the fold-changes of RNA and protein 
levels could be detected at 8 h and 24 h. 
The reason, why the majority of the proteins detected in the secretome approach 
(57 out of 72 proteins), was not detected in the transcriptome approach is unknown. 
However, this could result from the stringent threshold criteria applied in the 
transcriptome approach which might have excluded the corresponding RNAs of 
proteins which were detected in the secretome approach. 
The detected difference between fold-changes in RNA and protein levels is in 
accordance with work of Schwanhäusser et al.166. In a parallel quantification of cellular 
RNA and protein levels in mouse fibroblasts, they found a correlation between RNA 
and protein expression but also described variations in quantities. This was ascribed to 
alterations in translation rates. 
It should be mentioned that LIF has also been detected in the secretome approach 
(2.9-fold upregulated), but was slightly below the significance threshold (p=0.082) and, 
therefore, was not stated in the results. IL11, in contrast, is lacking glycosylation and 
therefore could not be detected in the secretome approach. 
In summary, for the majority of detected proteins (14/15) RNA and protein levels 
were regulated in equal directions by the treatment of human astrocytes with FGF1. No 
correlation of fold-changes in RNA and protein levels could be detected. Therefore, it 
might be misleading to draw conclusions about protein levels on the basis of the 
corresponding RNA level. This is not surprising as protein expression is regulated on 
multiple levels, including translation rate and protein degradation.  
Both methods, as applied in the present study, do have pros and cons (summarized 
in table 21). By merely applying one or the other method, FGF1-mediated aspects in 
human astrocytes would have been missed. This study clearly shows that the 
combination of a secretome- and transcriptome microarray analysis is superior to each 
analysis by itself. 
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Table 21: Advantages/disadvantages of the secretome and transcriptome approach 
 Advantages Disadvantages 
Secretome analysis Direct detection of protein expression: 
- No misinterpretation due to differences in 
RNA and protein induction 








- Detection of RNA coding for intra- and 
extracellular proteins 
- Identification of stimulatory pathways 
Changes on the RNA level: 
- Increase in RNA levels does not correlate 
with increase on protein levels 
5.3 FGF1-POSITIVE CELLS IN MS LESIONS 
FGF1 is known to exhibit widespread functions in the developing as well as in the 
adult brain. It is expressed by various cell types, in the CNS predominantly by neurons 
but also by glial cells153. In the secretome- and transcriptome microarray analysis, 
FGF1 was found to mediate the induction of a multitude of genes and proteins in 
human astrocytes. These pointed to functions of FGF1 in the regulation of 
remyelination, modulation of inflammation and remodeling of the ECM. To better 
understand FGF1-mediated effects in MS lesions, FGF1-positive cells in control brain 
as well as in different MS lesions were identified using IHC. It could be shown that 
subsets of oligodendroglia in white matter of control brain and NAWM in MS lesions 
were FGF1-positive. Additionally, subsets of neurons in gray matter of control brain 
were FGF1-positive. Hypertrophic astrocytes were found to be FGF1-positive in re- as 
well as in demyelinated lesions. In (chronic) active lesions, Iba-1/FGF1-double positive 
macrophages and microglia were observed. Furthermore, double staining with CD3 
and CD20 revealed FGF1-positive T and B cells in perivascular cuffs of active lesions. 
FGF1 in neurons. In the CNS, FGF1 was predominantly found to be synthesized by 
neurons24, 57, 153, 183. In the adult rat CNS, FGF1-positive neurons were found in spinal 
motor neurons and neurons related to the somatosensory system57 as well as in 
dopaminergic neurons of the substantia nigra24. In a study of Stock et al.183, differences 
in the cellular distribution of FGF1 between CNS compartments were determined. They 
compared the cerebral cortex, subcortical telencephalon, the thalamus, the 
hypothalamus, midbrain as well as brainstem and cerebellum183. Within the cerebral 
cortex only a subset of small to medium sized neurons was FGF1-positive which were 
predominantly localized in cortical layers IV and V. Furthermore, it was found that the 
staining pattern of FGF1 in neurons also depended on the neuronal population183. This 
is in accordance with the finding of FGF1-positive neuronal subsets in cortical sections 
of control brain (figure 20).  
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FGF1 in oligodendrocytes. Besides neurons, oligodendroglia in parts of the white 
matter in control brain as well as in NAWM surrounding MS lesions were detected to be 
FGF1-positive. Correspondingly, FGF1 staining of oligodendrocytes has been 
described for the white matter of spinal cord in adult mice201 in which double staining 
with MBP identified FGF1 in a subset of oligodendrocytes. Comparably, in the present 
study FGF1 was not detected in all but in subsets of oligodendroglia which mostly 
appeared to be focally accumulated. 
FGF1 in astrocytes. A prominent FGF1 staining was detected in hypertrophic 
astrocytes forming the glial scar in remyelinated and demyelinated MS lesions. Some 
astrocytes, with a rather mild hypertrophic phenotype localized in the NAWM were 
FGF1-negative. 
Although, in various immunohistochemical studies, apart from neurons, no FGF1-
positive cells could be detected24, 183, others reported in vitro FGF1 production in 
astrocytes83, 114. Furthermore, FGF1-positive astrocytes were detected in rodent187, 201 
and human CNS198. Interestingly, FGF1 expression in astrocytes was often described 
in response to stress or brain damage83, 114, 187. This includes in vitro FGF1 induction in 
rat astrocytes by long-term culture83 or by stimulation with corticosteroids114. 
Furthermore, FGF1 has been found to be upregulated in mouse brain at a post 
cryoinjury stage187. Here, FGF1 production was located to astrocytes in the peri-injury 
regions, especially in the foci of gliosis. Further support for the expression of FGF1 in 
reactive astrocytes comes from immunohistochemical studies describing FGF1 
expression in post-mortem tissue of Alzheimer patients. In brain specimen of Alzheimer 
patients, reactive FGF1-positive astrocytes were particularly localized in the 
surroundings of senile plaques94, 199. However, in Alzheimer’s disease not all GFAP-
positive astrocytes did express FGF1. It was hypothesized that FGF1 could participate 
to neurite abnormalities and glial proliferation due to its neurotrophic and gliotrophic 
effects. These findings are similar to the observation of the present study that FGF1-
positive astrocytes are localized in the glial scar of remyelinated and demyelinated 
lesions, whereas, FGF1-negative hypertrophic astrocytes can be found outside of the 
lesion in the NAWM. It is feasible that an autocrine FGF1-mediated mechanism 
participates in the proliferation of astrocytes and the formation of the glial scar. This 
would also match the detection of FGF1-mediated cell cycle regulation in astrocytes, as 
it was suggested from a pathway enrichment analysis performed with the data obtained 
in the transcriptome microarray analysis. Further support for this theory comes from 
studies identifying FGF1 as a potent mitogen for glial cells59, 159, 163, 168. FGF1 
expression in astrocytes of remyelinated MS lesions may contribute to the elevated 
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FGF1 levels which were previously observed by RT-qPCR in remyelinated MS lesions 
(Mohan et al., in preparation). 
FGF1 in active lesions. Analyzing FGF1 staining in (chronic) active lesion, subsets 
of microglia and macrophages as well as B and T lymphocytes were FGF1-positive. 
Previously, FGF1 was immunohistochemically identified in infiltrating macrophages in 
the pathology of various renal diseases157 and in alveolar macrophages in normal lung 
of mice76 and human97. In the CNS, previous studies reported about FGF1-positive 
macrophages and microglia invading an acute, chemically induced demyelinating 
lesion in the spinal cord of adult mice200. Comparable to our results, expression of 
FGF1 was limited to subsets of macrophages and microglia. Literature about FGF1 
expression in lymphocytes is limited. However, there are reports about FGF1 
expression in lymphocytes under different pathological conditions. FGF1-positive CD4 
and CD8 T cells were found in human tissue of different inflammatory renal 
diseases157. FGF1-positive, B cell-derived Hodgkin and Reed/Sternberg cells were 
detected in different subtypes of Hodgkin’s lymphoma91. Interestingly, in vitro evidence 
was found for FGF1 induction in glatiramer acetate-reactive Th1 and Th2 polarized cell 
lines224. Glatiramer acetate is a synthetic copolymer approved for the therapy of RR MS 
and was shown to have modulatory functions on the innate and adaptive immune 
response4. This argues for a FGF1 expression in lymphocytes in response to external 
stimuli or inflammatory processes which are not yet identified. FGF1-positive T cell, 
B cells and macrophages may contribute to the slightly elevated FGF1 expression 
which was observed by RT-qPCR in active MS lesions (Mohan et al., in preparation). 
To further investigate FGF1 expression in T and B cells, human adenoids were 
analyzed by IHC. Furthermore, tonsillar T and B cells were purified and FGF1 levels 
were determined by RT-qPCR. A small proportion of T cells, particularly in the germinal 
centers, stained FGF1-positive. Purified T cells exhibited low RNA levels of FGF1 
which also argues for a small subset of T cells expressing FGF1. B cells were not 
found to be FGF1-positive in adenoids and displayed only marginal FGF1 RNA levels.  
Taken together, FGF1 expression in MS brain was localized to different cell types. 
FGF1-positive subsets of neurons, oligodendrocytes, astrocytes as well as 
microglia/macrophages and lymphocytes were detected in different MS lesions. 
Remarkably, the number of FGF1-positive lymphocytes in perivascular cuffs of MS 
lesions was relatively high compared to the number of lymphocytes identified in tonsils. 
Furthermore, macrophages were not detected to express FGF1 in lymphatic tissue, 
whereas they did in (chronic) active MS lesions. Further studies have to address the 
mechanisms of FGF1 induction in the different cell types as well as the functions which 
might be regulated by FGF1 in MS lesion environment. 
Discussion 71 
5.4 CONCLUSIONS 
FGF1 is an abundant factor in human brain and was found to be upregulated in 
remyelinated MS lesions (Mohan et al., in preparation). 
In the present study, FGF1 protein was localized to the different cell types in MS 
lesions. FGF1-positive subsets of neurons in gray matter as well as oligodendrocytes in 
white matter of control brain and NAWM surrounding MS lesions were detected. FGF1-
positive astrocytes were identified in remyelinated and demyelinated MS plaques. In 
active lesions, microglia, macrophages and lymphocytes, located in perivascular cuffs, 
were found to be FGF1-positive. Mechanisms, regulating FGF1 in the different cell 
types remain to be analyzed. 
Using the in vitro myelinating culture system established in the present work, FGF1 
was found to promote myelination in an independent study (Mohan et al., in 
preparation). However, the mechanisms of FGF1-promoted myelination are not yet 
clear. 
This question was addressed in the present study. Functions of FGF1 on FGFR-
expressing human astrocytes in cell culture were explored. A transcriptome approach 
revealed the induction of RNAs which might be implicated in modulation of 
remyelination (LIF, IL8 and PTX3) and in the regulation of inflammation (PTX3, IL8, 
KCNN4, SPHK1, HMOX1, PTHLH, and NT5E). 
The indirect FGF1-mediated upregulation of factors with pro-myelinating activity in 
astrocytes could contribute to the enhanced remyelination and to CNS recovery. 
Additionally, FGF1-dependent upregulation of factors involved in the inflammatory 
response, point to a modulatory role of FGF1 during acute inflammation. 
Results, obtained from a recently developed secretome approach, pointed to a 
participation of FGF1 signaling in the remodeling of the ECM. By disintegration of the 
ECM, FGF1 could support cell growth, cell migration and the release of cytokines. 
Additionally, FGF1-dependent upregulation of MMP9 could be involved in the 
degradation of the parenchymal basement membrane and facilitate the extravasation 
of leukocytes. 
Currently, the potential therapeutic application of various members of the FGF 
family is investigated because of their mitogenic, cytoprotective and angiogenic 
properties26. A more detailed understanding of FGF1-mediated effects in the CNS 
could provide a therapeutic basis for the promotion of repair mechanisms in MS. 
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ATP Adenosine triphosphate 
AUC Area under the curve 
BSA Bovine serum albumin 
c Concentration 
CD Cluster of differentiation 
cDNA Complementary DNA 
CNS Central nervous system 
CNTF Ciliary neurotrophic factor 
COL Collagen 
CSF Cerebrospinal fluid 
CX3CL1 Chemokine (C-X3-C motif) ligand 1 
CXCL Chemokine (C-X-C motif) ligand 
Da Dalton 
DAB 3.3'-Diaminobenzidine 
DAPI 4'.6-diamidino-2-phenylindol dihydrochlorid 
DEG Differentially expressed genes 
DIV Days in vitro 
DM Differentiation medium 
DM/I Differentiation medium with insulin 
DMEM Dulbecco's modified eagle medium 
EAE Experimental autoimmune encephalomyelitis 
EDSS Expanded disability status scale 
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor 
EGR1 Early growth response 1 
ELISA Enzyme-linked immunosorbent assay 
FFPE Formalin fixed paraffin embedded 
FGF1 Fibroblast growth factor 1 
FGFR Fibroblast growth factor receptor 
FRS2 FGFR substrate 2 
GAPDH Glycerinaldehyd-3-phosphat-Dehydrogenase 
GFAP Glial fibrillary acidic protein 
HBSS Hank's balanced salt solution 
HE Haematoxylin and eosin 
HEPES 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
HIER Heat induced epitope retrieval 
HMOX1 Heme oxygenase (decycling) 1 
Iba-1 Ionized calcium-binding adapter molecule-1 
Abbreviations 85 
Ig Immunoglobulin 
IGF1 Insulin-like growth factor 1 
IHC Immunohistochemistry 
IL Interleukin 
iNOS Inducible nitric oxide synthases 
KCNN4 Potassium intermediate/small conductance calcium-activated channel, subfamily 
N, member 4 
LFA-1 Lymphocyte function-associated antigen-1 
LFB Luxol fast blue 
LIF Leukemia inhibitory factor 
LIMMA Linear models for microarray data 
LTα Lymphotoxin α 
ManNAz Tetraacetyl-N-azidoacetyl-mannosamine  
MCP1 Monocyte chemoattractant protein 1 
MHC Major histocompatibility complex  
MMP Matrix metalloproteinases 
MOG Myelin oligodendrocyte glycoprotein 
MS Multiple sclerosis 
NaHCO3 Sodium bicarbonate 
NMO Neuromyelitis optica 
ns Not significant 
NT5E 5'-nucleotidase, ecto (CD73) 
OPCs Oligodendrocyte precursor cells 
PBS Phosphate buffered saline 
PDGF Platelet-derived growth factor 
PerCP Peridinin chlorophyll protein 
PI3K Phosphoinositide-3-kinase 
PLC Phospholipase C 
PM Plating medium 
PP Primary progressive 
PPIA Peptidylprolyl isomerase A (human cyclophilin A) 
PTX3 Pentraxin 3, long 
qPCR Quantitative polymerase chain reaction 
Ras MAPK Ras mitogen activated protein kinase 
RPE R-Phycoerythrin 
RR Relapsing remitting 
RT Reverse transcription 
RT-qPCR Reverse transcription quantitative PCR 
S1P Sphingosine 1-phosphate 
S1P1 S1P receptor 1 
SD Standard deviation 
86 Abbreviations 
SDS Sodium dodecyl sulfate 
SEM Standard error of the mean 
SEMA Semaphorin 
SP Secondary progressive 
SPECS Secretome protein enrichment with click sugars 
SPHK1 Sphingosine kinase 1 
TCEP Tris-(2-carboxyethyl)-phosphine-hydrochloride 
TGFβ Transforming growth factor β 
TIMP Tissue inhibitor of metalloproteinases 
TMB 3,3',5,5'-tetramethylbenzidine 
TNFα Tumor necrosis factor α 
Tris Tris(hydroxymethyl)aminomethane 
TSA Tyramide signal amplification 
VCAM1 Vascular cell adhesion protein 1 
VLA-4 Very late antigen-4 
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8 RESOURCES 
Primary human astrocytes. Primary human astrocytes were kindly provided by 
Prof. Dr. Francesca Aloisi (ISS, Rome, Italy). 
 
Human tonsils. Tissue from human tonsils was obtained from PD Dr. Klaus Stelter 
(Klinik und Poliklinik für Hals-Nasen-Ohrenheilkunde, Klinikum LMU, Germany). 
 
Transcriptome microarray analysis. Analysis of the raw data (Affymetrix 
GeneChip® Human Gene 1.0 ST arrays) was performed in the laboratory of Prof. Dr. 
Cinthia Farina (San Raffaele Scientific Institute, Milan, Italy). 
 
Secretome analysis. Sample processing, subsequent to FGF1 stimulation, and 
mass spectrometry analysis was performed by Dr. Peer-Hendrik Kuhn (DZNE, Munich, 
Germany). 
 
LFB/HE and KiM1P staining. The LFB/HE and the KiM1P staining of the chronic 
active lesion shown in figure 22 were performed in the laboratory of Prof. Dr. Tanja 




9.1 APPENDIX 1: MICROARRAY SCREENING 
The RNA concentration of the samples used for the microarray screening varied 
between 85 ng/µl and 201 ng/µl and was sufficient for microarray analysis 
(table 22, column 2). The A260/280 ratios of all samples were found to be > 2.0, 
indicating no contamination with proteins (table 22, column 3). The purity ratio of 
A260/A230 was sufficient for nine out of the 12 samples and < 1.0 only for the following 
samples: “Control 8h 2”, “FGF1 24 h 1” and “FGF1 24 h 3” (table 22, column 4). Due to 
the good overall quality of these samples regarding the other parameters, they were 
used for further analysis. All RNA integrity numbers were similar and ≥ 8.9 indicating an 
excellent RNA quality and ensured a good comparability of the samples in the 
microarray analysis (table 22, column 5).  
The achieved cRNA yield ranged from 29 μg to 81 μg, which was above the 
recommended threshold of 20 μg proposed by Affymetrix (table 22, column 6). The 
second cycle cDNA yield ranged from 7 μg to 9 μg which exceeded the recommended 
threshold of 6 µg proposed by Affymetrix (table 22, column 7). The quality of cRNA, 
second cycle cDNA and fragmented sense strand cDNA was controlled using the 2100 
Bioanalyzer. Results indicated successful cRNA and cDNA synthesis as well as 
fragmentation of all samples (not shown). Therefore, all samples could be applied in 
the hybridization reaction. 
 
Table 22: RNA concentration and quality, cRNA yield, cDNA yield 










Control 8 h 1 149 2.08 1.30 8.90 75 8 
Control 8 h 2 139 2.11 0.38 9.80 65 7 
Control 8 h 3 166 2.09 1.08 10.00 53 8 
FGF1 8 h 1 179 2.07 1.50 10.00 81 9 
FGF1 8 h 2 134 2.09 2.13 9.60 76 8 
FGF1 8 h 3 147 2.08 1.42 9.90 73 8 
Control 24 h 1 85 2.07 2.20 9.80 45 8 
Control 24 h 2 91 2.06 1.55 10.00 50 8 
Control 24 h 3 103 2.04 2.06 9.80 47 8 
FGF1 24 h 1 180 2.07 0.94 9.70 51 8 
FGF1 24 h 2 182 2.07 1.65 9.80 51 8 
FGF1 24 h 3 201 2.10 0.90 9.80 29 7 
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The overall good performance was checked by calculating the area under the curve 
(AUC) of positive controls against negative controls, in which 0.5 represented a random 
match and 1.0 a perfect match. All arrays had AUC values > 0.8 and, therefore, 
specificity of signals could be demonstrated (table 23, column 2). The labeling process 
was monitored by examination of hybridization intensities of poly-A spike-in controls 
(B. subtilis genes: lys, phe, thr, and dap). Signal intensities should appear in the 
following order: dap > thr > phe > lys. Typical behavior as well as high sensitivity and 
accuracy of target preparation could be verified for all samples (figure 26, A). The high 
accuracy and sensitivity of the hybridization reaction as well as the staining and 
washing procedures were checked by comparing the signal intensities of 3’- and 5’-
hybridization control probe sets. The signal intensities for both probe sets should be 
placed in the following order: cre > bioD > bioC > bioB, which could be demonstrated 
for all the samples (figure 26, B).  
 
 
Figure 26: Quality control of transcriptome microarray analysis 
C: control (medium treated); FGF1: 10 ng/ml FGF1 and 5 U/ml heparin 
(A) Signal intensities for poly-A spike-in controls. (B) Signal intensities of 3’- and 5’-hybridization control 
probesets. 
The unbiased performance of the array was checked by calculating the ratio of the 
signal intensities of the 3’- and the 5’-probesets. All the ratios were < 3, demonstrating 
an unbiased performance (table 23, column 3 to 6).  
Taken together, the total RNA samples were found to have overall excellent RNA 
quality. They were successfully analyzed on Affymetrix GeneChip® Human Gene 
1.0 ST arrays and the quality criteria were fulfilled for all analyzed samples. 
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Table 23: AUC and ratio of signal intensities of 3’- and 5’-hybridization controls 
 Ratio 3’- / 5’-probesets of hybridization controls 
Sample ID AUC cre bioB bioC bioD 
Control 8 h 1 0.9058 0.9739 0.9917 1.0719 1.025 
Control 8 h 2 0.9041 0.9743 0.9892 1.0787 1.0294 
Control 8 h 3 0.9088 0.9989 0.9995 1.0569 1.0193 
FGF1 8 h 1 0.902 0.9735 0.9871 1.076 1.032 
FGF1 8 h 2 0.9085 0.9693 1.0045 1.067 1.0236 
FGF1 8 h 3 0.9015 0.9978 0.997 1.0816 1.029 
Control 24 h 1 0.9034 0.9812 0.998 1.0855 1.0296 
Control 24 h 2 0.8991 0.9906 0.9938 1.0929 1.0285 
Control 24 h 3 0.907 0.9937 0.9936 1.0633 1.019 
FGF1 24 h 1 0.898 0.9592 0.9819 1.0827 1.0377 
FGF1 24 h 2 0.9055 0.9726 0.9912 1.0749 1.0286 
FGF1 24 h 3 0.9036 0.9831 0.9849 1.0796 1.0231 
9.2 APPENDIX 2: TRANSCRIPTOME APPROACH 
RNA levels of genes upregulated after 8 h and 24 h FGF1 treatment 
Gene name RefSeq-no. Probe ID Gene description 8 h FC 24 h FC 
MMP1 NM_002421 7951271 Matrix metallopeptidase 1 (interstitial 
collagenase) 
2.2302 8.7368 
SLC16A6 NM_001174166 8017843 Solute carrier family 16, member 6 
(monocarboxylic acid transporter 7) 
3.1361 6.3291 
MPP4 NM_033066  8058273 Membrane protein, palmitoylated 4 (MAGUK 
p55 subfamily member 4) 
1.6453 6.1999 
STC1 NM_003155  8149825 Stanniocalcin 1 2.7252 4.7958 
ANGPTL4 NM_139314  8025402 Angiopoietin-like 4 4.7091 4.3668 
GFPT2 NM_005110  8116418 Glutamine-fructose-6-phosphate 
transaminase 2 
3.0658 4.2560 
RGS4 NM_001102445 7906919 Regulator of G-protein signaling 4 3.3535 4.1901 
SEMA7A NM_003612  7990345 Semaphorin 7A, GPI membrane anchor 
(John Milton Hagen blood group) 
3.1396 4.1673 
EMP1 NM_001423  7954090 Epithelial membrane protein 1 3.0680 3.7633 
RPSAP52 NR_026825  7964733 Ribosomal protein SA pseudogene 52 2.9191 3.6028 
DUSP6 NM_001946  7965335 Dual specificity phosphatase 6 3.4226 3.4630 
PTX3 NM_002852  8083594 Pentraxin 3, long 3.0199 3.4033 
RGS2 NM_002923  7908409 Regulator of G-protein signaling 2, 24kDa 2.6080 3.3080 
SCG5 NM_001144757 7982366 Secretogranin V (7B2 protein) 1.8474 3.2399 
SLAMF8 NM_020125  7906486 SLAM family member 8 1.9222 3.2188 
PLAT NM_000930  8150509 Plasminogen activator, tissue 1.9372 3.2087 
IL8 NM_000584  8095680 Interleukin 8 2.3215 3.2043 
HMGA2 NM_003483  7956867 High mobility group AT-hook 2 2.4129 3.1053 
ITGA2 NM_002203  8105267 Integrin, alpha 2 (CD49B, alpha 2 subunit of 
VLA-2 receptor) 
2.1076 3.0553 
C13orf33 NM_032849  7968351 Chromosome 13 open reading frame 33 1.5389 2.9861 
SLC20A1 NM_005415  8044499 Solute carrier family 20 (phosphate 
transporter), member 1 
2.5578 2.9758 
iv Appendix 
EDNRA NM_001957  8097692 Endothelin receptor type A 1.9355 2.9373 
PLAUR NM_002659  8037374 Plasminogen activator, urokinase receptor 1.9707 2.8845 
KRTAP2-4 NM_033184  8015210 Keratin associated protein 2-4 1.7975 2.8564 
KRT34 NM_021013  8015268 Keratin 34 2.1095 2.8413 
HMOX1 NM_002133  8072678 Heme oxygenase (decycling) 1 2.2461 2.7947 
KRTAP2-1 NM_001123387 8015208 Keratin associated protein 2-1 1.8109 2.6783 
SERPINA9 NM_175739  7981084 Serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 9 
1.4185 2.6445 
ARHGAP22 NM_021226  7933469 Rho GTPase activating protein 22 2.0990 2.5753 
MGLL NM_007283  8090433 Monoglyceride lipase 1.7052 2.5587 
MIR221 NR_029635  8172266 MicroRNA 221 2.6787 2.5530 
MLPH NM_024101  8049487 Melanophilin 1.9122 2.5485 
SHC3 NM_016848  8162216 SHC (Src homology 2 domain containing) 
transforming protein 3 
1.6137 2.5167 
PODXL NM_001018111 8142981 Podocalyxin-like 1.5496 2.4964 
ADAMTS14 NM_139155  7928147 ADAM metallopeptidase with 
thrombospondin type 1 motif, 14 
1.5304 2.3702 
TFPI2 NM_006528  8141016 Tissue factor pathway inhibitor 2 2.3622 2.3686 
TNFAIP6 NM_007115  8045688 Tumor necrosis factor, alpha-induced protein 
6 
1.9252 2.3609 
HAS2 NM_005328  8152617 Hyaluronan synthase 2 2.9637 2.3394 
PNP NM_000270  7973067 Purine nucleoside phosphorylase 1.6645 2.3287 
RGMB NM_001012761 8107100 RGM domain family, member B 2.1325 2.3276 
CD9 NM_001769  7953291 CD9 molecule 1.4575 2.2806 
CNIH3 NM_152495  7910022 Cornichon homolog 3 (Drosophila) 2.0185 2.2621 
ARHGAP18 NM_033515  8129458 Rho GTPase activating protein 18 1.5691 2.2199 
DUSP5 NM_004419  7930413 Dual specificity phosphatase 5 2.2691 2.2177 
SMAGP NM_001033873 7963280 Small cell adhesion glycoprotein 1.6696 2.2152 
CORO2B NM_006091  7984475 Coronin, actin binding protein, 2B 1.5794 2.2100 
E2F7 NM_203394  7965094 E2F transcription factor 7 1.8905 2.2006 
PLAU NM_002658  7928429 Plasminogen activator, urokinase 1.5921 2.1556 
SPRY4 NM_030964  8114797 Sprouty homolog 4 (Drosophila) 2.0936 2.1527 
SPOCD1 NM_144569  7914467 SPOC domain containing 1 1.5975 2.1472 
ERRFI1 NM_018948  7912157 ERBB receptor feedback inhibitor 1 2.2777 2.1298 
TM4SF1 NM_014220  8091411 Transmembrane 4 L six family member 1 1.5164 2.1072 
WNK4 NM_032387  8007363 WNK lysine deficient protein kinase 4 1.9211 2.0977 
CDK17 NM_002595  7965652 Cyclin-dependent kinase 17 1.6159 2.0876 
EREG NM_001432  8095728 Epiregulin 2.4678 2.0858 
SPRY2 NM_005842  7972217 Sprouty homolog 2 (Drosophila) 2.1107 2.0839 
MT1L NR_001447  7995793 Metallothionein 1L (gene/pseudogene) 1.4700 2.0359 
ASAM NM_024769  7952341 Adipocyte-specific adhesion molecule 1.4059 1.9858 
MT1X NM_005952  7995838 Metallothionein 1X 1.5018 1.9663 
NT5E NM_002526  8120967 5'-nucleotidase, ecto (CD73) 1.4099 1.9545 
EGR1 NM_001964  8108370 Early growth response 1 3.6266 1.9492 
TBX3 NM_016569  7966690 T-box 3 1.9109 1.9490 
DNMBP NM_015221  7935660 Dynamin binding protein 1.5534 1.9308 
NETO1 NM_138966  8023828 Neuropilin (NRP) and tolloid (TLL)-like 1 1.7473 1.9044 
TMEM200A NM_052913  8122038 Transmembrane protein 200A 1.7218 1.9004 
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ITPRIP NM_033397  7936242 Inositol 1,4,5-triphosphate receptor 
interacting protein 
1.6575 1.8926 
AKAP12 NM_005100  8122807 A kinase (PRKA) anchor protein 12 1.5919 1.8719 
KRT19 NM_002276  8015349 Keratin 19 1.5295 1.8383 
FZD8 NM_031866  7933075 Frizzled homolog 8 (Drosophila) 1.5577 1.8369 
KCNG1 NM_002237  8067029 Potassium voltage-gated channel, subfamily 
G, member 1 
1.7128 1.8181 
VCAM1 NM_001078  7903358 Vascular cell adhesion molecule 1 1.7414 1.8136 
SLCO4A1 NM_016354  8063923 Solute carrier organic anion transporter 
family, member 4A1 
1.6585 1.7991 
TMCC3 NM_020698  7965510 Transmembrane and coiled-coil domain 
family 3 
1.5637 1.7974 
HBEGF NM_001945  8114572 Heparin-binding EGF-like growth factor 2.4184 1.7852 
MT1E NM_175617  7995797 Metallothionein 1E 1.4396 1.7723 
FGF16 NM_003868  8168463 Fibroblast growth factor 16 1.8014 1.7715 
KCNN4 NM_002250  8037408 Potassium intermediate/small conductance 
calcium-activated channel, subfamily N, 
member 4 
1.7143 1.7656 
HOXB2 NM_002145  8016438 Homeobox B2 1.4062 1.7505 
VEGFC NM_005429  8103822 Vascular endothelial growth factor C 1.4453 1.7430 
SH2B3 NM_005475  7958749 SH2B adaptor protein 3 1.6869 1.7424 
FGF5 NM_004464  8096050 Fibroblast growth factor 5 1.4500 1.7379 
CHST11 NM_018413  7958202 Carbohydrate (chondroitin 4) 
sulfotransferase 11 
1.4214 1.7260 
RALA NM_005402  8132406 V-ral simian leukemia viral oncogene 
homolog A (ras related) 
1.4628 1.7176 
TMEM51 NM_001136218 7898115 Transmembrane protein 51 1.4686 1.7154 
SPHK1 NM_182965  8010061 Sphingosine kinase 1 1.4716 1.6998 
RAGE NM_014226  7981346 Renal tumor antigen 1.7203 1.6983 
BCL2A1 NM_001114735 7990818 BCL2-related protein A1 1.7736 1.6896 
RASA1 NM_002890  8106784 RAS p21 protein activator (GTPase 
activating protein) 1 
1.5217 1.6786 
RASSF8 NM_007211  7954469 Ras association (RalGDS/AF-6) domain 
family (N-terminal) member 8 
1.6241 1.6770 
LIF NM_002309  8075310 Leukemia inhibitory factor (cholinergic 
differentiation factor) 
1.9161 1.6604 
STX1A NM_004603  8140113 Syntaxin 1A (brain) 1.4711 1.6542 
SMTN NM_134269  8072413 Smoothelin 1.5489 1.6484 
PHLDA1 NM_007350  7965040 Pleckstrin homology-like domain, family A, 
member 1 
1.7026 1.6437 
FOSL1 NM_005438  7949532 FOS-like antigen 1 1.4513 1.6326 
JUN NM_002228  7916609 Jun proto-oncogene 1.7369 1.6177 
HK2 NM_000189  8042942 Hexokinase 2 1.7026 1.6042 
BNC1 NM_001717  7991080 Basonuclin 1 1.4799 1.5939 
MFSD2A NM_001136493 7900365 Major facilitator superfamily domain 
containing 2A 
1.5920 1.5643 
BCL10 NM_003921  7917338 B-cell CLL/lymphoma 10 1.6987 1.5608 
HS3ST3B1 NM_006041  8005097 Heparan sulfate (glucosamine) 3-O-
sulfotransferase 3B1 
1.5557 1.5584 
WNT5A NM_003392  8088180 Wingless-type MMTV integration site family, 
member 5A 
1.5298 1.5427 
IER2 NM_004907  8026163 Immediate early response 2 1.6113 1.5420 
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HPCAL1 NM_134421  8040238 Hippocalcin-like 1 1.4894 1.5397 
CCIN NM_005893  8155200 Calicin 1.5670 1.5289 
KCNG1 NM_002237  8067033 Potassium voltage-gated channel, subfamily 
G, member 1 
1.4543 1.5201 
ASB1 NM_001040445 8049657 Ankyrin repeat and SOCS box-containing 1 1.4155 1.5137 
AGPAT9 NM_032717  8096116 1-acylglycerol-3-phosphate O-
acyltransferase 9 
1.5180 1.5018 
SLC4A7 NM_003615  8085914 Solute carrier family 4, sodium bicarbonate 
cotransporter, member 7 
1.4949 1.5006 
IRX3 NM_024336  8001449 Iroquois homeobox 3 1.4011 1.4958 
PTHLH NM_198965  7962000 Parathyroid hormone-like hormone 1.9606 1.4920 
SLC25A37 NM_016612  8145281 Solute carrier family 25, member 37 1.4638 1.4517 
DPF3 NM_012074  7979963 D4, zinc and double PHD fingers, family 3 1.5239 1.4451 
GPR68 NM_003485  7980765 G protein-coupled receptor 68 1.4904 1.4360 
SPSB1 NM_025106  7897449 SplA/ryanodine receptor domain and SOCS 
box containing 1 
1.4113 1.4159 
AREG NM_001657  8095736 Amphiregulin 1.6490 1.4019 
FC: fold-change 
Double underlined genes are known from literature to be implicated in MS and their induction was verified 
using RT-qPCR. 
9.3 APPENDIX 3: SECRETOME APPROACH 
Secreted and glycosylated proteins induced by FGF1 treatment  
Protein name ACCN    
(UniProt KB) 
Gene name FC  
Sec   
48 h 
FC 





CD44 antigen P16070 CD44 26.99 - 1.53 
Matrix metalloproteinase-9 (67 kDa; 82 kDa)  P14780 MMP9 24.12 - - 
Semaphorin 7A O75326 SEMA7A 10.98 3.13 4.17 
Interstitial collagenase P03956 MMP1 10.84 2.23 8.74 
Polyubiquitin-C; Ubiquitin P0CG48 UBC;UBB 8.51 - - 
CUB domain-containing protein 1 Q9H5V8 CDCP1 6.90 - 2.00 
Angiopoietin-related protein 4 Q9BY76 ANGPTL4 5.94 4.71 4.37 
Integrin alpha-3 (heavy and light chain) P26006 ITGA3 5.55 - - 
Metalloproteinase inhibitor 1 P01033 TIMP1 5.30 - 1.51 
Chondroitin sulfate proteoglycan 4 Q6UVK1 CSPG4 4.33 - - 
C-type mannose receptor 2 Q9UBG0 MRC2 3.97 - - 
Low-density lipoprotein receptor H0YMD1 LDLR 2.48 - - 
Cathepsin B (heavy and light chain) P07858 CTSB 2.45 - - 
Integrin beta-1 P05556 ITGB1 2.41 - - 
Tyrosine-protein kinase receptor UFO P30530 AXL 2.40 - - 
CD166 antigen Q13740 ALCAM 2.29 - - 
Neogenin Q92859 NEO1 2.25 - - 
Neuropilin-1 O14786 NRP1 2.18 - 1.64 
Inactive tyrosine-protein kinase 7 Q13308 PTK7 2.13 - -1.41 
Plasminogen activator inhibitor 1 P05121 SERPINE1 2.11 - - 
Transmembrane protein 132A Q24JP5 TMEM132A 2.06 - - 
4F2 cell-surface antigen heavy chain P08195 SLC3A2 2.03 - - 
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Low-density lipoprotein receptor-related protein 1 (85 
kDa; 515 kDa; intracellular domain) 
Q07954 LRP1 2.02 - - 
Cadherin-13 P55290 CDH13 2.00 - - 
Endothelin-converting enzyme 1 P42892 ECE1 1.91 - - 
Glypican-1; Secreted glypican-1 P35052 GPC1 1.81 - - 
CD109 antigen Q6YHK3 CD109 1.79 - - 
Nidogen-1 P14543 NID1 1.75 - - 
Elongation factor 2 Q6PK56 EEF2 1.71 - - 
Attractin O75882 ATRN 1.61 - - 
Hepatocyte growth factor receptor P08581 MET 1.57 - - 
Prostaglandin F2 receptor negative regulator Q9P2B2 PTGFRN 1.17 - - 
Collagen alpha-1(VI) chain P12109 COL6A1 1.16 - - 
Adipocyte enhancer-binding protein 1 Q8IUX7 AEBP1 -1.07 - - 
Heat shock protein HSP 90-beta Q6PK50 HSP90AB1 -1.13 - - 
Proteasome activator complex subunit 2 Q9UL46 PSME2 -1.23 - - 
Carbohydrate sulfotransferase 3 Q7LGC8 CHST3 -1.27 - - 
Tenascin P24821 TNC -1.29 - - 
Carbohydrate sulfotransferase 14 Q8NCH0 CHST14 -1.39 - - 
Beta-galactosidase P16278 GLB1 -1.46 - - 
Macrophage colony-stimulating factor 1 P09603 CSF1 -1.47 - - 
Follistatin-related protein 3 O95633 FSTL3 -1.51 - -1.40 
Myosin-9 P35579 MYH9 -1.52 - - 
Granulins (-1; -2; -3; -4; -5; -6; -7; Acrogranulin; 
Paragranulin) 
P28799 GRN -1.53 - - 
Thrombospondin-1 P07996 THBS1 -1.56 - - 
Complement C1s subcomponent (heavy and light 
chain) 
P09871 C1S -1.61 - - 
ADP-sugar pyrophosphatase Q9UKK9 NUDT5 -1.62 - - 
Platelet-derived growth factor C (latent form; receptor-
binding form) 
Q9NRA1 PDGFC -1.63 - - 
Calsyntenin-2 Q9H4D0 CLSTN2 -1.69 - -1.50 
Plectin Q15149 PLEC -1.71 - - 
Multiple epidermal growth factor-like domains protein 
6 
O75095 MEGF6 -1.74 - - 
Mammalian ependymin-related protein 1 A4D1W8 UCC1;EPD
R1 
-1.77 - - 
Serine protease 23 O95084 PRSS23 -1.80 - -1.56 
Alpha-actinin-4 O43707 ACTN4 -1.81 - - 
Heparan sulfate N-deacetylase/N-sulfotransferase 1 P52848 NDST1 -1.87 - -1.41 
Periostin B1ALD8 POSTN -2.00 - - 
Fructose-bisphosphate aldolase A P04075 ALDOA -2.02 - - 
Brother of CDO Q9BWV1 BOC -2.08 - - 
Protein-lysine 6-oxidase P28300 LOX -2.09 - - 
Microfibrillar-associated protein 2 P55001 MFAP2 -2.15 - - 
Connective tissue growth factor P29279 CTGF -2.22 - - 
Soluble scavenger receptor cysteine-rich domain-
containing protein SSC5D 
A1L4H1 SSC5D -2.26 - - 
Actin-related protein 2/3 complex subunit 2 O15144 ARPC2 -2.30 - - 
Stanniocalcin-2 O76061 STC2 -2.82 - -1.81 
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Insulin-like growth factor-binding protein 3 P17936 IGFBP3 -3.12 - -1.98 
Collagen alpha-2(V) chain P05997 COL5A2 -3.32 - - 
Collagen alpha-2(IV) chain; Canstatin P08572 COL4A2 -3.33 - - 
Decorin P07585 DCN -3.36 - - 
Protein KIAA1199 Q8WUJ3 KIAA1199 -3.69 -1.45 -4.01 
Collagen alpha-1(I) chain P02452 COL1A1 -3.72 - - 
Collagen alpha-2(I) chain P08123 COL1A2 -4.07 - - 
Transforming growth factor beta-2 P61812 TGFB2 -5.19 - -1.93 
ACCN: Accession number; FC: fold-change; Sec: Secretome; Trans: Transcriptome 
Double underlined proteins were detected in the transcriptome and the secretome approach. These 
proteins are also summarized in table 19. 
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